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Abstract
Pyruvate dehydrogenase kinase 4 (PDK4) regulates pyruvate oxidation through the phosphorylation and
inhibition of the pyruvate dehydrogenase complex (PDC). The PDC catalyzes the conversion of pyruvate
to acetyl-CoA and it is an important control point in glucose and pyruvate metabolism. Previous studies
had reported that PDK4 gene expression is induced by thyroid hormone (T3). These studies did not
investigate the mechanisms by which T3 regulated PDK4 gene expression. I have examined the role of the
thyroid hormone receptor (TR), transcriptional coactivators especially the peroxisome proliferator
activated receptor gamma coactivator-1 (PGC-1α) and other transcription factors that act as accessory
factors in T3 actions.
Thyroid hormone receptors (TRα or TRβ) are part of the nuclear receptor family and have been implicated
in the induction of many genes by T3. The nuclear receptors constitute a broad class of transcription
factors that have the ability to bind to DNA and regulate the expression of the genes in a ligand dependent
manner. To identify a binding site for the TRβ in the promoter of the PDK4 gene, I transfected serial
deletions of this promoter ligated to the luciferase reporter gene into the human hepatoma (HepG2) cells.
The TRβ binding site was characterized by gel shift mobility assays, site directed mutagenesis and in vivo
and in vitro luciferase constructs transfection techniques. In addition, I have used the chromatin
immunoprecipitation (ChIP) technique to confirm the binding of the TRβ to the PDK4 gene promoter.
Transcription coregulators bind to nuclear receptors to facilitate or inhibit the transcription of the target
genes. I have explored the role of several coregulators including the transcriptional coactivator
peroxisome proliferator activated receptor gamma coactivator-1 (PGC-1α). Previous studies
demonstrated that PGC-1α could induce the PDK4 gene. Here, I found that T3 increases PGC-1α
abundance and association with the PDK4 gene. In addition, adenoviral shRNA-mediated knock-down of
PGC-1α reduced the T3 induction of PDK4 and several other genes. These data suggest that PGC-1α
participates in the T3 induction of multiple genes in the liver. In addition, I investigated the role of several
transcription factors including estrogen related receptor (ERRα), CCAAT/enhancer binding protein beta
(C/EBPß) and the forkhead transcription factor (FOXO1) in the activation of the PDK4 gene by T3. ERRα
and FoxO1 recruit PGC-1α to the proximal PDK4 promoter and are involved in the synergistic stimulation
of the PDK4 gene by T3 and PGC-1α. C/EBPß was identified as an important accessory factor in the T3
induction of the PDK4 gene. Knock-down of C/EBPß with adenoviral shRNA decreased both the basal
expression and T3 stimulation of PDK4. Overall, my results showed that T3 induces PDK4 gene
expression through a TRβ binding site in the promoter of the PDK4 gene and that the two transcription
coregulators PGC-1α and C/EBPβ enhance this induction.
Finally, I have tested the ability of T3 to induce a group of transcriptional regulators and metabolic genes.
After 24 hours, 27 gens were found to be induced by T3 including several coactivators. These results
suggest that T3 may induce a network of transcriptional regulators to further amplify the actions of T3.
Thus, my studies have characterized the mechanism of the activation of an important metabolic gene,
PDK4 gene, by T3 and identified the transcription factors that are involved in this mechanism. Also, my
studies have provided a broad insight of the hepatic transcription factors network that work coordinately
to facilitate the action of the T3 in the liver. This work may open a door to further investigate therapeutic
targets in this network to modulate metabolic disease processes that are affected by the thyroid
hormone.
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ABSTRACT
Pyruvate dehydrogenase kinase 4 (PDK4) regulates pyruvate oxidation through
the phosphorylation and inhibition of the pyruvate dehydrogenase complex (PDC). The
PDC catalyzes the conversion of pyruvate to acetyl-CoA and it is an important control
point in glucose and pyruvate metabolism. Previous studies had reported that PDK4 gene
expression is induced by thyroid hormone (T3). These studies did not investigate the
mechanisms by which T3 regulated PDK4 gene expression. I have examined the role of
the thyroid hormone receptor (TR), transcriptional coactivators especially the peroxisome
proliferator activated receptor gamma coactivator-1 (PGC-1α) and other transcription
factors that act as accessory factors in T3 actions.
Thyroid hormone receptors (TRα or TRβ) are part of the nuclear receptor family
and have been implicated in the induction of many genes by T3. The nuclear receptors
constitute a broad class of transcription factors that have the ability to bind to DNA and
regulate the expression of the genes in a ligand dependent manner. To identify a binding
site for the TRβ in the promoter of the PDK4 gene, I transfected serial deletions of this
promoter ligated to the luciferase reporter gene into the human hepatoma (HepG2) cells.
The TRβ binding site was characterized by gel shift mobility assays, site directed
mutagenesis and in vivo and in vitro luciferase constructs transfection techniques. In
addition, I have used the chromatin immunoprecipitation (ChIP) technique to confirm the
binding of the TRβ to the PDK4 gene promoter.
Transcription coregulators bind to nuclear receptors to facilitate or inhibit the
transcription of the target genes. I have explored the role of several coregulators
including the transcriptional coactivator peroxisome proliferator activated receptor
gamma coactivator-1 (PGC-1α). Previous studies demonstrated that PGC-1α could
induce the PDK4 gene. Here, I found that T3 increases PGC-1α abundance and
association with the PDK4 gene. In addition, adenoviral shRNA-mediated knock-down
of PGC-1α reduced the T3 induction of PDK4 and several other genes. These data
suggest that PGC-1α participates in the T3 induction of multiple genes in the liver. In
addition, I investigated the role of several transcription factors including estrogen related
receptor (ERRα), CCAAT/enhancer binding protein beta (C/EBPß) and the forkhead
transcription factor (FOXO1) in the activation of the PDK4 gene by T3. ERRα and
FoxO1 recruit PGC-1α to the proximal PDK4 promoter and are involved in the
synergistic stimulation of the PDK4 gene by T3 and PGC-1α. C/EBPß was identified as
an important accessory factor in the T3 induction of the PDK4 gene. Knock-down of
C/EBPß with adenoviral shRNA decreased both the basal expression and T3 stimulation
of PDK4. Overall, my results showed that T3 induces PDK4 gene expression through a
TRβ binding site in the promoter of the PDK4 gene and that the two transcription
coregulators PGC-1α and C/EBPβ enhance this induction.
Finally, I have tested the ability of T3 to induce a group of transcriptional
regulators and metabolic genes. After 24 hours, 27 gens were found to be induced by T3

v

including several coactivators. These results suggest that T3 may induce a network of
transcriptional regulators to further amplify the actions of T3.
Thus, my studies have characterized the mechanism of the activation of an
important metabolic gene, PDK4 gene, by T3 and identified the transcription factors that
are involved in this mechanism. Also, my studies have provided a broad insight of the
hepatic transcription factors network that work coordinately to facilitate the action of the
T3 in the liver. This work may open a door to further investigate therapeutic targets in
this network to modulate metabolic disease processes that are affected by the thyroid
hormone.
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CHAPTER 1: INTRODUCTION
This chapter provides an overview of the topics examined in this dissertation
including thyroid hormone biology, the functions of the transcription coregulators and
finally the role and the regulation of pyruvate dehydrogenase kinase 4.
1.1 Thyroid hormone
1.1.1 General biology
Thyroid hormone plays an important role on various aspects of metabolism,
development and differentiation of cells (Yen, 2001). The thyroid gland secretes the
thyroid hormones, T4 and the more biologically active form T3. Most of the T4
undergoes peripheral 5'-deiodination into the T3 form (Braverman et al., 1970; Kohrle,
2000). T3 increases the metabolic rate by stimulating almost every tissue in the body to
produce mitochondrial proteins and by increasing the oxygen utilization in cells
(Oppenheimer et al., 1987). Early studies showed that T3 treatment of hypothyroid rats
triggers RNA synthesis in liver and alters the transcription of target genes (Miksicek &
Towle, 1982; Tata et al., 1963; Tata & Widnell, 1966). T3 mediates its effect on gene
expression through binding to the thyroid hormone receptors (TRs) (Munoz et al., 1988;
Schueler et al., 1990). Thyroid hormone receptors belong to the superfamily of nuclear
hormone receptors, which are a class of ligand activated proteins that, when bound to
specific sequences of DNA serve as transcriptional regulators within the cell nucleus.
This family of nuclear receptors controls the development and differentiation of skin,
bone, behavioral centers in the brain as well as the continual regulation of reproductive
tissues and metabolism (Alaynick, 2008; Chung & Cooney, 2003; Francis et al., 2003).
Currently about 48 nuclear hormone receptors have been discovered in human and they
have been categorized according to their sequence homology into 6 subfamilies (Laudet,
1997; Zhang et al., 2004c).
The specific sequence that TRs bind to in the DNA sequence are known as T3
response elements (TREs). TRs can bind to these sequences with or without ligand to
produce its positive or negative regulation on the target genes (Rastinejad et al., 1995;
Samuels et al., 1988). A putative consensus hexamer half-site sequence of
[(G/A)GGT(C/G)A] was characterized for the TREs, based on mutational and sequence
comparison studies. There is considerable variation in the primary nucleotide sequence as
well as the number, spacing, and orientation of the half-sites (Cheng, 2000; Williams &
Brent, 1995). The half-sites for the TREs can be arranged as palindromes (TREpal), direct
repeats (DRs), and inverted palindromes (IPs) and the optimal spacing between these
half-site arrangements are zero, four, and six nucleotides, respectively. The most common
TRE contains a direct repeat separated by 4 nucleotides (DR4) (Glass, 1994; Williams &
Brent, 1995).
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1.1.2 Thyroid hormone receptors
There are two major TR isoforms encoded on separate genes, designated as TRα
and TRβ. The primary transcript for each gene can be alternatively spliced, generating
four thyroid hormone-binding receptors, namely TRα1, TRα2, TRβ1, TRβ2 and TRβ3
(Chassande, 2003; Williams, 2000). All the TR isoforms bind thyroid hormone and
mediate gene regulation except for TRα2 which encodes an altered ligand binding domain
of unknown function (Munroe & Lazar, 1991). The TR isoforms in human, rat and mouse
are highly homologous with respect to their amino acid sequences (Lazar, 1993). The
TRs have several conserved domains including an A/B domain in the amino terminus and
a DNA binding domains containing two zinc fingers. Importantly, the ligand binding
domain (LBD) contains the activation function-2 (AF-2) peptide that interacts with
coactivators. TRα1, TRα2, TRβ1 and TRβ3 are expressed in most of the rat, mouse, and
human tissues although their tissue specific abundance differs greatly (Bradley et al.,
1992; Hodin et al., 1990). However, the TRβ2 is restricted to pituitary and particular brain
regions of the rodent (Bradley et al., 1992; Hodin et al., 1990; Lechan et al., 1994; Wood
et al., 1991) and has not yet been detected in the human. Although both TRα1 and TRβ1
are expressed in most tissues, TRα1 is highly expressed in skeletal muscle and brown
adipose tissue whereas the TRβ1 is the most abundant form of TR in liver, kidney and
brain (Lazar, 1993). In heart, TRα1 is most predominant TR isoform and is responsible
for mediating thyroid hormone action in myocardiocytes, while in liver TRβ1 mediates
the action of the thyroid hormone (Dillmann & Gloss, 2002).
TRs can bind to the TREs as a monomer, homodimer or heterodimer with the
retinoid X receptor (RXR). This heterodimerization with RXR enables the TRs to bind to
asymmetric TREs and direct repeats separated by four nucleotides. In the great majority
of genes, TR binds as a heterodimer with RXR (Glass, 1994; Ribeiro et al., 1994).
Thyroid hormone plays an important role in the regulation of genes involved in
metabolism and development. The development of transgenic and knockout mouse
models for the different TRs isoforms have helped us in understanding the molecular
mechanisms of T3 action in normal and disease states. For example, the role of the
thyroid hormone in pituitary gland had been identified by knockout studies done on the
TRβ2 isoform, and it showed that TRβ2 may be playing the predominant role in regulating
the thyroid stimulating hormone (TSH) (Abel et al., 1999). In heart knockout studies for
the TRα1 and TRβ had showed that T3 maintains baseline heart rate through the TRα1,
whereas T3 stimulates heart rate through TRβ (Johansson et al., 1999). In addition, the
role of T3 in lipid synthesis and degradation had been examined in mice expressing the
mutant TRβ. These mice had elevated serum cholesterol levels compared with control
animals in both hypothyroid and hyperthyroid states (Hayashi et al., 1996). Moreover,
using a mouse model of resistance to thyroid hormone where a point mutation in the
ligand-binding domain of TRβ abolished its ability to bind to T3, Koshi Hashimoto
reported cross talk between the liver X receptor α (LXRα) and the TRβ to regulate the
cholesterol uptake and metabolism in liver. (Hashimoto et al., 2006). On the other hand,
TRß-/- mice showed lowered stimulation of the cholesterol 7-α hydroxylase gene
(CYP7A) mRNA level by T3 but not in TRα1-/- mice. These results indicate that TRß not
2

the TRα is the mediator of T3 action on CYP7A gene, the rate limiting enzyme in the
process of the degradation of the cholesterol into bile acids, and consequently it is one of
the major regulators of cholesterol metabolism in vivo. However, T3-deficient TRß-/- mice
showed an augmented CYP7A response after challenge with dietary cholesterol, and
these animals did not develop hypercholesterolemia to the extent as did wild type
controls. The latter results lend strong support to the concept that TRs may exert
regulatory effects in vivo independent of T3 (Gullberg et al., 2000).
1.1.3 Thyroid hormone effects on glucose and fatty acids metabolism
Lipid and glucose metabolism are among the many physiological processes that
are regulated by thyroid hormone. In fact, there is a strong link between thyroid hormone
disorders and number of widespread metabolic diseases including diabetes (Crunkhorn &
Patti, 2008; Johnson, 2006; Wu, 2007), obesity (Kozlowska & Rosolowska-Huszcz,
2004; Naslund, 2000; Ribeiro, 2008) and cardiovascular disease (Gomberg-Maitland &
Frishman, 1998; Klein & Ojamaa, 2001). Along with heart and muscle, the liver is one of
the main organs affected by T3 (Weitzel, 2003).
In liver, T3 increases the abundance of a number of genes potentially involved in
hepatic triglyceride production, including spot 14 and fatty acid transporter protein as
well as a range of genes involved in hepatic lipogenesis and low density lipoprotein
receptor expression (Feng et al., 2000; Ness & Zhao, 1994). Paradoxically, T3
simultaneously induces genes involved in lipolysis including lipoprotein lipase (Pykalisto
et al., 1976; Wahrenberg et al., 1994).
Regarding glucose metabolism, T3 stimulates almost all aspects of carbohydrate
metabolism, including enhancement of insulin-dependent entry of glucose into cells and
increased gluconeogenesis through elevating the transcription of key gluconeogenic
enzymes, such as glucose-6-phosphatase (G6P) and phosphoenolpyruvate carboxykinase
(PEPCK) (Fowden et al., 2001; Park et al., 1997). In addition, T3 promotes
glycogenolysis to generate free glucose (Johnson, 2006).
Previous studies had detected at least two different gene expression pattern
mediated by T3. Whereas limited number of genes were rapidly induced by T3 within 6
hours only of in vivo T3 treatment, the majority of T3 regulated genes needed 24-48
hours to be induced by the T3 treatment (Weitzel et al., 2003a; Weitzel et al., 2001). This
observation led to the assumption that T3 can mediate gene expression by several
mechanisms. One direct mechanism for the T3 mediated gene regulation is through
binding of T3 to its TRE site on targeted gene promoter. The other mechanism is through
the induction of an intermediate factor such as, the peroxisome proliferator activated
receptor gamma coactivator-1 or the nuclear respiratory factor or CCAAT/enhancer
binding protein beta that can in turn promote the induction of the targeted gene (Park et
al., 1997; Weitzel et al., 2001; Zhang et al., 2004b).
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Although detailed investigations have been performed to identify the mechanism
by which T3 regulated different metabolic genes including phosphoenolpyruvate
carboxykinase (PEPCK), carnitine palmitoyltransferase 1a (CPT-1a), apolipoprotein B
(ApoB) and uncoupling protein 3 (UCP3) (de Lange et al., 2007; Jackson-Hayes et al.,
2003; Mukhopadhyay et al., 2003; Park et al., 1999; Zhang et al., 2004b), the mechanism
of the induction of the pyruvate dehydrogenase kinase 4 (PDK4) gene by T3 had not been
identified (Sugden et al., 1996). Understanding the mechanism of activation of PDK4 by
T3 is an important step to fully understand the metabolic effect of the T3 on fatty acid
and glucose metabolism as PDK4 is a key regulator in the pyruvate metabolism, which in
turn affects both glucose and fatty acid metabolism (Jeoung & Harris, 2008; Sugden &
Holness, 2002).
1.1.4

Mechanism of the regulation of genes by thyroid hormone

The thyroid gland produces tetraiodothyronine (T4), triiodothyronine (T3), and
3,3',5'-triiodothyronine (rT3), however, the T4 is quantitatively the major secretory
product (Moreno et al., 2008). There are three types of deiodinases, and they are
responsible for the peripheral 5'-deiodination of T4 and T3 (Bianco et al., 2002; Kuiper et
al., 2005). The first type is deioidinase I (D1) which is found in peripheral tissues such as
liver and kidney and is responsible for the conversion of the majority of T4 to T3 in the
blood circulation, while deiodinase II (D2) is predominant in brain, pituitary, and brown
adipose tissue and primarily converts T4 to T3 for intracellular use. The third type is
deioidinase III (D3), which is responsible for the generation of reverse T3 (rT3), which is
the inactive form of the hormone. D3 is found primarily in placenta, brain, and skin (Yen,
2001). D1 and D3 are also involved in the further degradation of T3 or T4 to distinct
diiodothyronines: 3, 5-diiodothyronine (T2); 3, 3'-diiodothyronine (3, 3'-T2); and 3', 5’diiodothyronine (3', 5'-T2). And finally these, in turn, can be transformed into
monoiodothyronine (T1) and subsequently into thyronine (T0) (Moreno et al., 2008).
T3 binds to the thyroid hormone receptor (TR) which in turn binds to the thyroid
response element (TRE) to modulate the transcription of target genes. However, the
unliganded TRs can still bind to the TRE in the promoter of the targeted gene and can
repress basal transcription of positively T3 regulated genes (Baniahmad et al., 1992;
Brent et al., 1989). This basal repression is due to the direct interaction of unliganded
TRs with corepressor molecules that typically posses the histone deacetylase activity and
can interfere with the assembly of a functional preinitiation complex at the promoter of
the target gene (Baniahmad et al., 1993; Tong et al., 1995). Nuclear receptor corepressor
(NCoR) and the silencing mediator for retinoic acid receptor and thyroid receptor
(SMRT) are corepressors that interact with unligaded TR (Horlein et al., 1995; Lee et al.,
1995). The consensus LXXI/HIXXXI/L sequences within the NCoR and SMRT interact
with the amino acid residues on helices 3, 5, and 6, which are part of the ligand pocket
and hinge region of the TRs (Nagy et al., 1999; Perissi et al., 1999). These corepressors
interacts with other repressors as Sin 3 and histone deacetylase 1 (HDAC1), which in turn
promotes histone deactylation and results in basal transcription repression (Heinzel et al.,
1997; Nagy et al., 1997).
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When the ligand T3 is bound to the TR, it triggers significant conformational
changes (Bourguet et al., 2000), including the repositioning of the helix 12 containing the
core of AF-2 in the TR LBD (Glass & Rosenfeld, 2000), that results in release of the
corepressor complex and recruitment of a coactivator complex to enhance transcription of
the target gene (Onate et al., 1995). Most of the characterized coactivators interact with
the LBDs of the TRs, through helical LXXLL motifs present within these coactivators
(Heery et al., 1997). Several coactivators for the thyroid hormone transcription induction
have been identified including the CREB binding protein (CBP) and the p300 protein
complex, steroid receptor coactivator-1 (SRC-1) and PGC-1α (Chakravarti et al., 1996;
Kamei et al., 1996; Rosenfeld et al., 2006; Weiss et al., 1999; Wu et al., 2002; Zhang et
al., 2004b). These coactivators such as the CREB/p300 complex in turn interact and
recruit the PCAF (p300/CBP-associated factor) to TRE site of the target gene. The PCAF
has a histone acetyltransferase activity (HAT) which promotes hisone acetylation and
transcription activation (Ogryzko et al., 1998).
Therefore, the TR can shift between the unligaded and liganded form with T3
causing the association or dissociation of coactivators or corepressors of the transcription
machinery for the target genes (Figure 1.1) (Yen, 2001; Yen et al., 2006). As I
mentioned before T3 can increase cardiac function via the TRα while elevating hepatic
metabolism via TRβ. Thus, developing therapeutic agents that can promote the induction
of metabolic genes by activating specific isoform of the TR can be beneficial for treating
metabolic diseases as hypercholesteremia or obesity without provoking T3 cardiac side
effects. Preliminary studies in animals with TRß selective agonists have led to a lowering
of the triglyceride and cholesterol levels in animal models with less cardiac side effects
(Baxter et al., 2004; Grover et al., 2004; Perra et al., 2008; Trost et al., 2000). All these
facts show that understanding of the mechanism by which T3 regulate metabolic genes
can lead to the identification of more therapeutic targets within its network of regulated
genes for curing of related metabolic diseases.
1.2 Transcription factors and coactivators
1.2.1 General biology
Transcription factors and their coregulators coordinately regulate many biological
programs at the transcriptional level (Handschin & Spiegelman, 2006; Schrem et al.,
2002). Transcription factors control gene expression by binding to specific sequences
frequently in the promoter upstream of the DNA of target genes and thereby control the
transcription of their genetic information from DNA to RNA (Karin, 1990; Latchman,
1997). Transcription factors are composed of two essential functional regions: a DNAbinding domain and a transactivation domain. The DNA-binding domain is composed of
amino acids that recognize specific DNA bases, while the activator domain of
transcription factors contain the amino acids responsible for interacting with the
components of the transcriptional apparatus (RNA polymerase) and with other regulatory
proteins (transcription coactivators) (Agalioti et al., 2000; Senger et al., 2000).
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Transcription coregulators are those proteins that either activate or repress the
transcription of specific genes by interacting and regulating the transcription factors
(Glass & Rosenfeld, 2000). Transcription coactivators are the coregulators that activate
gene transcription, while those that repress it are known as corepressors. Transcriptional
coactivators or corepressors regulate the transcription by binding to other DNA-bound
factors without directly contacting DNA themselves (McKenna et al., 1999; Xu, 2005).
Two different mechanisms have been identified for transcription coregulators to regulate
the transcription of genes. The first mechanism for transcription coregulators is to modify
chromatin structure through covalent modification of histones by acetylation,
phosphorylation or methylation (Glass & Rosenfeld, 2000; Nowak & Corces, 2004;
Stewart et al., 2005). The second mechanism is to modify the conformation of chromatin
by an ATP-dependent process through altering chromatin structure by changing the
location or conformation of the nucleosome. These structural changes do not involve
covalent modification, and can either activate or repress the transcription (Aoyagi et al.,
2005; Kingston & Narlikar, 1999).
Based on the structure of its DNA-binding domain, transcription factors are
typically categorized into four groups including: basic domains, zinc-coordinating
domains, helix-turn-helix domains and beta-scaffold domains with minor grove contacts
(Stegmaier et al., 2004). The thyroid hormone receptor (TR) belongs to a zinc finger type
of transcription factors, while the CCAAT/enhancer binding protein beta (C/EBPβ)
belongs to the transcription factors with basic domains (leucine zipper type). On the other
hand, one common feature of nuclear receptor coactivators is that they contain one or
more LXXLL binding motifs. Different examples of transcription coactivators are listed
here, androgen receptor associated protein, cAMP response element-binding proteinbinding protein (CBP), coactivator-associated arginine methyltransferase 1 (CARM1),
steroid receptor coactivator (SRC), p300/CBP associating factor (p/CAF), and
proliferator activated receptor gamma coactivator 1 (PGC-1) (Cai et al., 2005; El
Messaoudi et al., 2006; Xu et al., 1999).
In this dissertation I am focusing on the effect of two transcription factors the TR
and the C/EBPβ on the activation of the PDK4 gene and the role of one transcription
coactivator, the PGC-1α. I have discussed the thyroid receptor biology and function in the
first part of this chapter and I will give an overview on the PGC-1α and the C/EBPβ in
the following part of the introduction.
1.2.2 PGC-1α as a transcription coactivator
Mitochondrial biogenesis, hepatic gluconeogenesis, and β-oxidation of fatty acids
are among many metabolic processes that are regulated by the transcription coactivator
proliferator activated receptor gamma coactivator-1 alpha (PGC-1α) (Puigserver &
Spiegelman, 2003). PGC-1α belongs to a family of transcriptional coactivators that
includes PGC-1β and PGC-1 related coactivator (PRC) (Finck & Kelly, 2006). PGC-1α
and PGC-1β are expressed in brown adipose tissue (BAT), heart, skeletal muscle, brain,
kidney and liver (Finck & Kelly, 2006), but there is less information about the expression
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patterns of PRC (Andersson & Scarpulla, 2001). Physiological conditions that demand
increased mitochondrial energy production such as exercising, fasting and cold exposure
highly induce the expression of PGC-1α in skeletal muscle, in the heart, liver and brown
adipose tissue (Baar et al., 2002; Lehman et al., 2000; Puigserver et al., 1998; Rhee et al.,
2003; Terada et al., 2002). Interestingly, fasting but not cold exposure induces PGC-1β,
indicating that there are unique regulatory mechanisms of regulation for each coactivator
and each activator may be involved in different metabolic pathways (Lin et al., 2002; Lin
et al., 2003).
PGC-1 has been implicated in the activation of many transcription factors
including a number of nuclear receptors such as the peroxisome proliferator-activated
receptors (PPAR) both the α and the β/δ isoforms (Vega et al., 2000; Wang et al., 2003),
retinoid receptors (Puigserver et al., 1998), glucocorticoid receptor (Knutti et al., 2000),
estrogen receptor (Knutti et al., 2000; Puigserver et al., 1998), farnesyl X receptor (FXR)
(Zhang et al., 2004a), pregnane X receptor (PXR) (Bhalla et al., 2004), hepatic nuclear
factor-4 (HNF-4) (Rhee et al., 2003), liver X receptor (LXR) (Lin et al., 2005b), and the
estrogen-related receptors (ERRs) (Huss et al., 2002; Schreiber et al., 2003).
PGC-1α was originally discovered as a cold-inducible transcription coactivator of
adaptive thermogenesis in brown adipose tissue (BAT) (Puigserver et al., 1998). PGC-1α
promotes mitochondrial biogenesis both in BAT and skeletal muscles through regulating
the nuclear respiratory factors (NRF-1 and NRF-2) (Leone et al., 2005; Wu et al., 1999).
Recent evidence also implicates PGC-1α in the regulation of glucose metabolism in
muscles as it activates expression of glucose transporter 4 (GLUT4) in cultured skeletal
muscle cells by coactivating myocyte enhancer factor-2 (MEF-2c) (Michael et al., 2001).
Moreover, PGC-1α regulated fatty acid oxidation and fuel selection in muscle by
activating the expression of the gene encoding pyruvate dehydrogenase kinase 4 via its
NR partner, ERRα (Wende et al., 2005). Finally in liver and heart, PGC-1α promotes
different metabolic processes. First, PGC-1α activate expression of PPARα target genes
involved in hepatic and cardiac fatty acid oxidation (Huss & Kelly, 2004; Leone et al.,
2005; Vega et al., 2000). Second, PGC-1α coactivates HNF-4α and FOXO1 to drive
expression of genes involved in gluconeogenesis in liver (Puigserver et al., 2003). Third,
PGC-1α activates mitochondrial biogenesis in cultured cardiac myocytes (Lehman et al.,
2000).
PGC-1α knockout mice further emphasized its important role for appropriate
adaptation to the metabolic and physiologic stressors. Leone et al showed that PGC-1α -/mice were unable to maintain core body temperature following exposure to cold,
consistent with an altered thermogenic response (Leone et al., 2005). Also, they develop
hepatic steatosis after a short period of starvation due to a combination of reduced
mitochondrial respiratory capacity and an increased expression of lipogenic genes (Leone
et al., 2005). On the other hand, the Spiegelman group reported that PGC-1α -/- mice are
paradoxically lean and resistant to diet-induced obesity and that they did not develop
hepatic steatosis. They showed diminished expression of genes involved in mitochondrial
fatty acid oxidation, the TCA cycle, and oxidative phosphorylation (Lin et al., 2004). The
mechanistic basis for the dissimilarities between the 2 lines of PGC-1α -/- mice is unclear
(Finck & Kelly, 2006). However, both of them reported that PGC-1α -/- mice are cold
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intolerant and they have a marked vacuolar lesions in the central nervous system together
with compromised the capacity of their hearts to perform basal and strenuous aerobic
work. Moreover, M. Patti had supported the central role of the PGC-1 system in human
body metabolism as she reported that decreased PGC-1α and PGC-1β expression in
human may be responsible for decreased expression of NRF-dependent genes,
contributing to the metabolic disturbances characteristic of insulin resistance in type 2
diabetes mellitus patients (Patti et al., 2003).
The expression and activity of PGC-1α are linked to a variety of upstream cellular
signaling pathways. Glucocorticoids and cAMP increased PGC-1α gene transcription in
liver (Bernal-Mizrachi et al., 2003; Puigserver et al., 1998). While in muscles, the AMPactivated protein kinase (AMPK), calcineurin A and calcium/calmodulin–dependent
protein kinase (CaMK) and p38 mitogen-activated protein kinase (p38 MAPK) have been
shown to activate PGC-1α (Fan et al., 2004; Schaeffer et al., 2004; Zong et al., 2002).
The upstream signaling events and downstream gene regulatory actions for the PGC-1α
coactivator in different body tissues are illustrated in Figure 1.2 (Finck & Kelly, 2006;
Lin et al., 2005a).
The most important aspect regarding the PGC-1 coactivator system related to this
dissertation is the ability of PGC-1α to coactivate the thyroid receptor and to induce the
PDK4 gene (Puigserver et al., 1998; Wende et al., 2005). In addition, previous studies
had reported that T3 highly induced the hepatic PGC-1α mRNA expression (Weitzel et
al., 2001). Moreover, previous studies from our lab had reported that overexpression of
the PGC-1α enhanced the induction of carnitine palmitoyltransferase 1a (CPT-1a) by
thyroid hormone. All this information had linked the T3 effect on metabolic processes
with the PGC-1α, but the role of the PGC-1α in the induction of PDK4 by T3 had not
been investigated. Therefore, this dissertation aimed to answer this question, is the PGC1α is important for the hepatic action of T3 on PDK4 gene and other metabolic genes?
1.2.3 C/EBPβ as a transcription factor
The CCAAT/enhancer binding protein beta (C/EBPβ) is a heat-stable DNAbinding protein found in rat liver nuclei. It belongs to a distinct subfamily of transcription
factors called C/EBPs with several members (C/EBPα, C/EBPβ, C/EBPγ, C/EBPδ,
C/EBPε, and C/EBPζ). They are encoded by separate genes located on different
chromosomes (Landschulz et al., 1988; Williams et al., 1991). The C/EBPs are
characterized by their ability to regulate different metabolic genes through binding
selectively to the CCAAT motif in the promoters of these genes (Schrem et al., 2004).
This group of proteins shares the highly conserved two homologous domains, the Cterminal basic DNA binding domain and the leucine zipper dimerization domain. In
addition, they contain two other less homologous domains, the N-terminal activation
domain and the attenuation domain (Arizmendi et al., 1999).
The expression patterns for the C/EBP isoforms are quite different as the C/EBPα
is expressed in liver, adipose, intestine, lung, adrenal gland, placenta, ovary and
peripheral blood mononuclear cells (PBMCs), while both C/EBPβ and C/EBPδ are
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expressed in liver, intestine, lung and adipose tissue.C/EBPβ is also detectable in kidney,
heart, and spleen by Northern analysis in the mouse (Cao et al., 1991). On the other hand,
C/EBPε is expressed only in myeloid and lymphoid lineages. Finally, C/EBPγ and
C/EBPζ are expressed ubiquitously (Lekstrom-Himes & Xanthopoulos, 1998).
It is noteworthy that C/EBPs can bind to the DNA as homodimers or as
heterodimers with other transcription factors (Schrem et al., 2004). Previous studies had
demonstrated the ability of the C/EBP family to form hetrodimers with members of the
cAMP-responsive-element-binding protein/ activating transcription factor (CREB/ATF)
family of transcription factors especially ATF-2 and C/ATF (Fawcett et al., 1999;
Shuman et al., 1997; Vallejo et al., 1993). C/EBP-ATF heterodimers bind to selective
DNA sequences that are uniquely different than that for the C/EBP and ATF
homodimers, as the C/EBP-ATF heterodimers bind to a so-called C/EBP-ATF composite
site in the promoter region of regulated genes. C/ATF-C/EBPβ heterodimers bind to a
subclass of asymmetric cAMP response elements exemplified by those in the
phosphoenolpyruvate carboxykinase and proenkephalin genes (Vallejo et al., 1993).
C/EBPβ expression is highly induced by lipopolysaccharide (LPS), IL-6, IL-1,
dexamethasone, and glucagon, suggesting a role in the mediation of the inflammatory
response (Alam et al., 1992; An et al., 1996; Matsuno et al., 1996). In adipose tissue,
C/EBPβ is involved in the transcription of fat-specific genes (Christy et al., 1989; Yeh et
al., 1995) and participates in the differentiation of pre-adipocytes (Bezy et al., 2007;
Hamm et al., 2001). In addition, C/EBPβ regulates carbohydrate and lipid metabolism
through binding and activating a variety of genes encoding key metabolic enzymes
including, but not limited to, phosphoenolpyruvate carboxykinase (PEPCK) and tyrosine
aminotransferase (Garlatti et al., 1993; Park et al., 1990; Park et al., 1999; Wang et al.,
1996), fatty acid synthesis enzyme acetyl-CoA carboxylase (Tae et al., 1994) and the
albumin gene (Friedman et al., 1989).
Several hormones including insulin, glucocorticoids and thyroid hormone
regulate the transcription of the C/EBPβ and through this regulation they further control
the expression of gluconeogenic genes (Duong et al., 2002; Ghosh et al., 2001;
Menendez-Hurtado et al., 1997; Park et al., 1999). However, the most relevant point
regarding this dissertation is the effect of thyroid hormone on the expression of C/EBPβ
that had been reported by Menendez-Hurtado (Menendez-Hurtado et al., 1997). He found
that during development, congenital hypothyroidism caused a significant decrease in both
C/EBPα and C/EBPβ gene expression at early stages of postnatal development in liver
(Menendez-Hurtado et al., 1997). This effect was tissue-specific since thyroid hormone
had no effect on both C/EBPs mRNA levels in brown fat. Upon injection of those
hypothyroid animals with thyroid hormone, there was a slow recovery of hepatic C/EBPα
and C/EBPβ mRNA levels. Also, hypothyroid neonates had shown diminished C/EBPα
and C/EBPβ protein levels, and the kinetics of induction of these proteins by thyroid
hormone was faster than the one observed for the corresponding transcripts suggesting a
translational or post-translational regulation of these genes as the major component of
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thyroid hormone action on these proteins (Menendez-Hurtado et al., 1997). Also, studies
from our lab had linked C/EBPβ with the induction of PEPCK by thyroid hormone (Park
et al., 1999). These information led us to investigate the role of C/EBPβ in induction of
another important metabolic gene, the PDK4, by thyroid hormone.

1.3 Pyruvate dehydrogenase kinase 4 (PDK4)
1.3.1 General biology
The pyruvate dehydrogenase complex (PDC) catalyzes the irreversible oxidative
decarboxylation of pyruvate into acetyl-CoA. This reaction links the utilization of
glycogen, glucose, and lactate with the citric acid cycle as well as fatty acid oxidation and
synthesis, since acteyl-CoA can be used for fatty acid and cholesterol synthesis in the
liver and fatty acid synthesis in adipose tissue. Prolonged fasting or high fat diets
inactivate the PDC in order to minimize loss of pyruvate carbon to conserve it for
maintaining the blood glucose levels needed through gluconeogensis. Another important
reason for inactivating the PDC is to promote the usage of fatty acids as their primary
energy source in as many tissues as possible. This in turn conserves body protein because
amino acids are not oxidized for energy and less amino acid carbon has to be used for
glucose synthesis (Randle, 1986; Sugden et al., 2001b).
All these observations indicate that regulating PDC is an important step in fuel
selection for energy production in animals during different nutritional and hormonal
states. Thus, the regulation of PDC is critical in glucose and fatty acids metabolism. PDC
is regulated by the reversible phosphorylation reaction. Pyruvate dehydrogenase kinase
(PDK) inactivates PDC by phosphorylation and pyruvate dehydrogenase phosphatase
(PDP) activates PDC by dephosphorylation. Figure 1.3 illustrates the role of the PDK
and PDP genes in the overall regulation process of the PDC activity (Sugden & Holness,
2003).
1.3.2 The role of the PDK in the regulation of the PDC
The mammalian pyruvate dehydrogenase complex is composed of three
components: Pyruvate dehydrogenase (E1), the dihydrolipoamide acetyltransferase
subunits (E2) and the dihydrolipoamide dehydrogenase (E3). E2 forms the core of the
complex, while E1 is the enzyme responsible for decarboxylation of pyruvate. E1 binds
noncovalently to an E1-binding domain on E2 as heterotetrameric α2β2 structure. E3 is
the enzyme responsible for oxidation of the reduced lipoyl groups of E2 and the
subsequent production of NADH, and it binds to the complex by the E3-binding protein
(E3BP), as twelve E3-binding proteins anchor 12 E3 homodimers to each pyruvate
dehydrogenase complex. Thus, each pyruvate dehydrogenase complex is composed of
216 subunits (60 E2, 60 E1α, 60 E1β, 12 E3BP, and 24 E3) that sum up to about 9.5 MD
(Harris et al., 2002).
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Although PDC activity is directly inhibited by the acetyl-CoA and NADH, the
two byproducts of fatty acid and pyruvate oxidation, covalent modification of the PDC at
the serine residues appears to be more important for regulating the PDC activity (Harris
et al., 2002). Two regulatory enzymes are involved in this covalent modification, the
PDK which inactivates the PDC through phosphorylation and the PDP which activate the
PDC through dephosphorylation. Four PDK isoenzymes (PDK1, PDK2, PDK3 and
PDK4) and two PDP isoenzymes (PDP1 and PDP2) are expressed in mammals (BowkerKinley et al., 1998; Huang et al., 1998). The phosphorylation and the dephosphorylation
occur at three serine residues number 203, 264 and 271 on the α-subunit of the E1
element of the PDC (Harris et al., 2002; Sugden & Holness, 2003).

1.3.3 PDK gene expression
PDK consists of two subunits, the catalytically active α-subunit and the regulatory
β-subunit. Four isoenzymes of PDK have been identified in mammalian tissues (PDK1,
PDK2, PDK3 and PDK4) (Bowker-Kinley et al., 1998; Kwon & Harris, 2004; Rowles et
al., 1996). The primary structure of PDK was determined for the first time by isolating a
cDNA encoding a 48-kDa form of PDK, later termed PDK from a rat heart cDNA library
(Popov et al., 1993). Based on analysis of the deduced amino acid sequences and crystal
structures studies, it had been suggested that PDK does not belong to the eukaryotic
serine/threonine protein kinases but rather it resembles the prokaryotic histidine protein
kinases. Therefore, it had been assigned to the ATPase/kinase superfamily (composed of
bacterial histidine protein kinases, DNA gyrases, and molecular chaperone Hsp90)
(Bowker-Kinley et al., 1998; Popov et al., 1993; Steussy et al., 2001).
There is 66-74% homology in the primary structures between the four PDK
isoenzymes: PDK3 and PDK4 are the most distinct and PDK1 and PDK2 the most
conserved (Popov et al., 1994). Each PDK isoform is extremely similar in sequence
between species, and PDK1 and PDK2 are >95% identical between rat and human
(Sugden & Holness, 2003). The PDK2, PDK3, and PDK4 share the same molecular
weight which corresponds to a 45-kDa, while only PDK1 has molecular weight of 48
KDa (Sugden & Holness, 2003).
The mammalian PDK isoenzymes exhibit tissue-specific expression patterns
(Bowker-Kinley et al., 1998). PDK1 expression has been detected in heart (Sugden et al.,
2000b; Wu et al., 1998), the pancreatic islet (Sugden et al., 2001a) and skeletal muscle
(Peters et al., 2001). PDK2 is expressed ubiquitously with particularly high expression in
heart, liver, and kidney (Bowker-Kinley et al., 1998), while PDK3 is expressed in testis,
kidney and brain (Huang et al., 1998). Finally, PDK4 is highly expressed in several
tissues, including heart (Sugden et al., 2000b; Wu et al., 1998), skeletal muscle (Holness
et al., 2002; Holness et al., 2000; Peters et al., 2001), liver (Holness et al., 2003; Sugden
et al., 2002), kidney (Bowker-Kinley et al., 1998; Sugden et al., 2001b) and the
pancreatic islet (Sugden et al., 2001a).
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PDK isoenzymes show different kinetic parameters for phosphorylation site
specificity in the regulation of PDC activity. As I mentioned before, the phosphorylation
of α-subunit of the E1 element of the PDC, occurs at three specific serine residues,
serine-264 (designated phosphorylation site 1), serine-271 (phosphorylation site 2) and
serine-203 (phosphorylation site 3) (Harris et al., 2002; Holness & Sugden, 2003; Sugden
& Holness, 2003). PDC can be inactivated by phosphorylation of each site alone,
although phosphorylation of site 1 is most rapid and site 3 phosphorylation least rapid.
All four PDKs exhibit higher activity towards site 1 of free E1 compared with sites 2 and
3. PDK2 exhibits the highest activity and PDK3 the lowest activity towards site 1. Hence,
PDK2 activity may account for much of the short-term inhibition of PDC observed on the
transition from the fed to the fasted state through phosphorylation of site 1. PDK4
exhibits a much higher activity towards site 2 compared with PDK1, PDK2 and PDK3
(Korotchkina & Patel, 2001). All four PDKs can phosphorylate sites 1 and 2, but site 3
can be phosphorylated only by PDK1, this was demonstrated using recombinant mutant
proteins of the E1 element of the PDC with a single functional phosphorylation site
(Kolobova et al., 2001; Korotchkina & Patel, 2001).
1.3.4 The role of the PDK4 gene in metabolic processes
PDK4 is expressed in heart, skeletal muscle, liver, kidney and in the pancreatic
islets. PDK4 is involved in the regulation of different metabolic processes within these
tissues. In heart for example, Harris et al reported marked increase in the abundance of
the PDK4 mRNA and protein in the hearts of rats that had been starved or rendered
diabetic with streptozotocin (Wu et al., 1998). Re-feeding of starved rats and insulin
treatment of diabetic rats very effectively reversed the increase in PDK4 protein, mRNA
levels and restored PDK enzyme activity to levels of chow-fed control rats. On the other
hand, little or no change in the amounts of PDK1 and PDK2 protein and the abundance of
their messages occurred in response to starvation and diabetes, indicating that control of
the amount of PDK4 is important in long-term regulation of the activity of the pyruvate
dehydrogenase complex in rat heart (Wu et al., 1998). Also, Mary Sugden reported that
hyperthyroidism and high fat feeding induced the expression of the PDK4 in hearts of
rats (Sugden et al., 2000b), while in liver high-fat feeding increased hepatic PDK2, but
not PDK4, protein expression whereas hyperthyroidism increased both hepatic PDK2 and
PDK4 protein expression (Holness et al., 2003). However, Huang et al reported that free
fatty acids are effective inducers of PDK4 expression in 7800C1 hepatoma cells (Huang
et al., 2002). Finally, high fat diets also induced the mRNA levels of the PDK4 gene in
skeletal muscle (Sparks et al., 2006). In addition, starvation induced the PDK4 gene
expression on both the RNA and protein levels not only in heart but in different
mammalian tissues including liver and kidney (Wu et al., 2000). All these facts suggest
that PDK4 may be the most important means of regulation of PDC activity during
starvation and in diet-induced obesity.
Therefore, PDK4 is involved in the regulation of glucose synthesis and fatty acid
oxidation as PDK4 upregulation during starvation may participate in directing available
pyruvate toward oxaloacetate formation in liver and kidney or to the lactate output rather
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than oxidation in case of skeltelatl muscle, with subsequent use for glucose synthesis for
entry into the gluconeogenic pathway and glucose synthesis (Sparks et al., 2006; Sugden
& Holness, 2002, 2003; Sugden et al., 2000a). Indeed, blood concentrations of glucose,
lactate, pyruvate, and alanine are low in PDK4-knockout (PDK4–/–) mice in the starved
state (Jeoung et al., 2006), consistent with an important role for PDK4 in maintaining
glucose levels during starvation. In addition, a recent PDK4–/– mice model showed lower
fasting blood glucose levels, a slightly improved glucose tolerance, and slightly greater
insulin sensitivity compared with wild-type mice (Jeoung & Harris, 2008). In the same
time, these PDK4–/– mice have elevated levels of nonesterified fatty acids, ketone bodies,
and branched-chain amino acids, consistent with slower rates of fatty acid oxidation.
Several transcription factors and coactivators have been implicated in the
regulation of the PDK4 gene expression and its downstream metabolic processes.
Activation of PPARα in vivo enhances hepatic and renal PDK4 protein expression in the
fed state promoting fatty acid oxidation (Huang et al., 2002; Sugden et al., 2001c).
Furthermore, the upregulation of hepatic and renal PDK4 protein expression normally
evoked in response to prolonged starvation is attenuated in PPARα-deficient mice
(Sugden et al., 2001b; Sugden et al., 2002). In contrast, skeletal muscle PDK4 gene
expression is suppressed by treatment of insulin-resistant rats with PPAR agonists,
promoting lipid entrapment in adipose tissue (Way et al., 2001). Interestingly, the
transcriptional coactivator PGC-1α that is in the core of this dissertation coactivates
PDK4 gene expression via the orphan nuclear receptor ERRα, exerting reciprocal
inhibitory influences on glucose catabolism while increasing alternate mitochondrial
oxidative pathways in skeletal muscle (Wende et al., 2005). In addition, recent studies
have also shown that the forkhead transcription factor FOXO1 and the glucocorticoid
receptor (GR), two additional potential PGC-1α partners, directly regulate PDK4
expression through consensus binding sites in the PDK4 gene promoter (Furuyama et al.,
2003; Kwon et al., 2004).
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CHAPTER 2: RESEARCH OBJECTIVES AND SPECIFIC AIMS
2.1 Research objectives
2.1.1 Characterize the regulation of PDK4 gene by thyroid hormone
Thyroid hormone (T3) is a key regulator of several processes including
development, differentiation and metabolic balance. Among its cellular metabolic effects
is the stimulation of fatty acid oxidation which is accompanied by a reduction in glucose
utilization. This particular effect can be explained, in part, by the ability of T3 to induce
the hepatic pyruvate dehydrogenase kinase (PDK4) gene expression. PDK4 suppresses
glucose oxidation by its inhibitory effect on the pyruvate dehydrogenase complex (PDC)
leading to an increase in fatty acid oxidation. T3 mediates its effect on gene expression of
other genes through binding to a thyroid hormone receptor which is a nuclear receptor
bound to the thyroid hormone response elements (TRE), frequently found in the
promoters of these target genes. Upon T3 binding to the thyroid hormone receptor, the
receptor undergoes a conformational change and recruits transcriptional coregulators
which facilitate the regulation of transcription by T3. Peroxisome proliferator-activated
receptor gamma coactivator-1 (PGC-1) and the CCAAT/enhancer binding protein
(C/EBP) are among these transcription coregulators. Previous studies in our lab have
demonstrated that PGC-1α and C/EBPβ are coactivators for the T3 induction of CPT-1a
and PEPCK, respectively. In addition, the forkhead transcription factor (FOXO1) and the
estrogen related receptor α (ERRα) are involved in the transcription regulation of PDK4
and other metabolic genes.
The induction of PDK4 gene by T3 was already documented; however, the
mechanism of this activation has not been investigated. Both, the TRE site in the
promoter of the PDK4 gene, and the transcription coregulators or the accessory factors
that are involved in this activation, have not been identified. Therefore, the first
hypothesis is that T3 activates PDK4 gene expression directly through a TRE site or
indirectly through the recruitment of transcription factors and accessory proteins or
through both mechanisms. To address this hypothesis, I characterized the PDK4 gene
promoter to locate a TRE site, and I also tested whether PGC-1α and C/EBPβ participate
in the T3 induction of the PDK4 gene. Also, the role of accessory factors as the ERRα
and the FOXO1 in this induction was examined.
2.1.2 Study the network of the transcription factors involved in the early response
of hepatic metabolic genes to thyroid hormone
Thyroid hormone regulates the expression of key metabolic genes including
phosphoenolpyruvate carboxykinase (PEPCK), carnitine palmitoyltransferase 1a (CPT1a), apolipoprotein B (ApoB) and uncoupling protein 3 (UCP3). However, the detailed
regulation of these genes is not fully understood. Moreover, previous studies
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demonstrated that T3 elevates the abundance of many transcription factors and
coactivators associated with mitochondrial biogenesis and lipid metabolism, such as
PGC-1α, ERRα and lipins. Therefore, the second hypothesis is that T3 stimulates
metabolism in part by increasing a network of transcription factors that induce metabolic
genes which may not contain a TRE site within their promoters. To address this
hypothesis, I have examined the effect of treating primary hepatocytes with T3 for 24
hours on 90 transcription factors and metabolic genes using superarray® real time PCR
technology.
2.2 Specific aims
The following are the specific aims for this dissertation:
•
•

SPECIFIC AIM 1: To characterize regulation of PDK4 gene by thyroid
hormone.
SPECIFIC AIM 2: To determine if T3 elevates expression of transcription
factors involved in the regulation of metabolic genes.
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CHAPTER 3: RESULTS AND EXPERIMENTAL PROCEDURES
3.1 Results
3.1.1 Identifying thyroid response elements (TREs) sites within the rPDK4 gene
promoter
Transcription of the PDK4 gene in the liver is induced by T3 in hyperthyroid rats
(Sugden et al., 1996). However, the position of the TRE within the rPDK4 gene had not
been determined. Therefore, the initial experiments were designed to localize and
confirm the region in the rPDK4 promoter required for inducing rPDK4 transcription by
T3. To localize a TRE in the PDK4 gene, I cotransfected HepG2 cells with rPDK4luciferase reporter constructs and an expression vector for TRß. First, I tested serial
deletions of the PDK4 promoter driving the luciferase reporter. Deletion of the 283
nucleotides between -1256 to -973 of the rPDK4 promoter abolished T3 responsiveness
from 5.1 ± 0.4 fold induction of the -1256/+78 rPDK4 luciferase vector to 0.8 ± 0.1 with
the -973/+78 rPDK4 luciferase vector (Figure 3.1A). The results are expressed as the
relative induction by T3 ± S.E. by comparing the T3 induction of vectors in the T3
treated cells to the non-treated ones. These data suggested that there was a TRE in this
region of the PDK4 promoter. I identified two potential TREs sites within this region of
the rPDK4 promoter. These TREs resemble the well established putative consensus
hexamer half-site sequence [(G/A)GGT(C/G)A] arranged as a direct repeat separated by
four nucleotides (DR4) which is the optimal binding site for TR/RXR. The putative
TREs are shown in Figure 3.1B together with a model of the rat PDK4 promoter
identifying the binding sites for ERRα, FOXO1 and PGC-1α.
I used site-directed mutagenesis of the PDK4 promoter to determine if either of
these potential TREs was important for the T3 induction. I disrupted the TRE1 by
changing the (GGT) in the second hexamer half site sequence into (AAC), and for the
TRE2 I changed the (GG) in its second hexamer half site into (AA). Primers used to
establish these mutations are listed in the experimental procedures section. To determine
the effect of these mutations on the T3 responsiveness, I transfected HepG2 cells with the
TRE1 mutant -1256/+78, TRE2 mutant -1256/+78 or the wild type -1256/+78 and tested
for T3 responsiveness by luciferase assays. TRE1 mutation caused a very significant
reduction in the T3 responsiveness (1.5 ± 0.2 fold, 60% less than the wild type 3.8 ± 0.4
fold, p = 0.0019). On the other hand, the TRE2 mutation did not alter the T3
responsiveness (4.4 ± 1.4, p = 0.299) (Figure 3.1C).
To further confirm the role of TRE1 in the T3 induction of the rPDK4 gene
promoter, we preformed an in vivo transfection into the livers of hyperthyroid rats
(Figure 3.1D). This experiment was conducted in collaboration with Dr. Gene Ness lab
in University of South Florida, and was performed by his graduate student Lindsey
Boone. The -1256/+78 rPDK4 luciferase vector wild type and the TRE1 mutant were
transfected by electroporation into different spots of the same rat liver.
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Figure 3.1: Localization and identification of the T3 responsive regions within the
rPDK4 promoter that enhance T3 responsiveness.
A. HepG2 cells were transiently transfected with 2 µg of different rPDK4 luciferase
reporters, 1 µg of RSV-TRβ, and 0.1 µg of TK-renilla. For hormone treatment, cells were
incubated either in serum-free DMEM or DMEM containing 100 nM T3 for 24 h. All
transfections were performed in duplicate and repeated three to six times. Luciferase and
renilla assays were performed in the same tube. Luciferase activity was corrected for both
protein content and renilla activity which served as a transfection control. Results are
expressed as the relative induction by T3 ± S.E. by comparing the T3 induction of vectors
in the treated cells to the non-treated ones. The significance is calculated in relative to the
shortest construct of the rPDK4-luciferase (-578/+78) (** = p value 0.001 to 0.01, *** =
p value <0.001). B. A model of the rat PDK4 promoter is shown that contains the sites
for the binding of the ERRα, FOXO1 and PGC-1α, also the sequence of the region
between -1256 to -973 for the rPDK4 promoter with underlined potential TREs. C.
HepG2 cells were transiently transfected with 2 µg of various -1256/+78 rPDK4
constructs, 1 µg of RSV-TRβ, and 0.1 µg of TK-renilla. For hormone treatment, cells
were incubated either in serum-free DMEM or DMEM containing 100 nM T3 for 24 h.
All transfections were performed in duplicate and repeated three to six times. Luciferase
assays were performed as described above. Results are expressed as the relative induction
by T3 ± S.E. by comparing the T3 induction of vectors in the treated cells to the nontreated ones. The significance is calculated in relative to the wild type rPDK4 -1256/+78luciferase (** = p value 0.001 to 0.01). D. Hypothyroid rats were transfected in vivo by
electroporation of liver as outlined in the experimental procedures section. The
transfection included the -1256/+78 wild type rPDK4-luciferase or the TRE1 mut
rPDK4- luciferase plasmids. TK-renilla was included as a control. The hypothyroid rats
were exposed to T3 three days before electroporation, with an additional half dose
injection prior to the day of electroporation. The values are the average of four
hypothyroid untreated rats and four T3 treated rats.
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Figure 3.1: (continued).
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Four hypothyroid rats were treated with T3 for 3 days before electroporation; with
an additional half dose injection the day prior to electroporation. Another hypothyroid
four rats were left untreated. In rats with T3 treatment, the expression of the wild type 1256/+78 rPDK4 luciferase promoter increased significantly by 3.1 ± 0.6 fold (p = 0.01)
in comparison to the mutant one, while in non-treated rats the induction of the wild type
form was not significantly different than that of the mutant form being only 1.4 ± 0.2 fold
(Figure 3.1D).
Finally, gel shift mobility assays were conducted with the wild type and the
mutants oligomers for the TRE1 site to test the ability of the TRβ to bind this element in
vitro. The results indicated that the TRβ can bind as a heterodimer with RXR to the wild
type of the TRE1 site. However, TRβ did not bind the mutated TRE (Figure 3.2). The
sequence of the oligomers used in this gel shift assays are indicated at the bottom of the
panel.
These data prove that we had discovered a TRE site localized within the -1112 to
-1096 region of the rPDK4 gene promoter, and that disruption of this site by site directed
mutagenesis reduced the ability of the T3 to induce the rPDK4 gene.
3.1.2 Association of the TRβ, PGC-1α and C/EBPβ with the PDK4 gene promoter in
vivo
Previous studies from our laboratory have implicated the involvement of both
peroxisome proliferator activated receptor gamma coactivator-1 alpha (PGC-1α) and
CCAAT/enhancer binding protein beta (C/EBPβ) in the activation of different metabolic
genes including the CPT-1a and PEPCK (Park et al., 1999; Song et al., 2004; Zhang et
al., 2004b). To determine whether TRβ, PGC-1α and C/EBPβ were associated with the
PDK4 gene in vivo, we conducted ChIP assays (Figure 3.3). Rat primary hepatocytes
were exposed to 100nM T3 for 24 h or left in serum-free media. We cross-linked the
hepatocytes with 1% formaldehyde prior to conducting immunoprecipitations with the
TRβ or PGC-1α or C/EBPβ antibodies. As a control, we used the immunoprecipitation
with rabbit pre-immune serum. We created PCR primers sets for the proximal, the TRE
region, and an upstream promoter region of the PDK4 gene, and they are listed in the
experimental procedures section. The upstream region served as a negative control. The
data from the ChIP assays indicated that prior to T3 treatment both TRβ and C/EBPβ are
associated with the proximal and the promoter region of the PDK4 gene around the TRE
site. However, they are not associated with the upstream region of the PDK4 gene and the
addition of T3 to hepatocytes did not increase the association of TRβ and C/EBPβ with
the proximal or the TRE region. On the other hand, the ChIP data show that prior to T3
treatment PGC-1α can associate to the proximal region of the PDK4 gene promoter, and
to a little extent to the TRE region of the promoter. Following treatment of hepatocytes
with T3, the association of PGC-1α with the proximal region of the PDK4 gene increased
by 1.85 ± 0.2 fold but T3 did not increase its association with the TRE region of the
promoter (Figure 3.3). The TRβ, C/EBPβ and PGC-1α were associated to different
extents with both the proximal and the TRE regions of the PDK4
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Figure 3.2: TRβ binding site in the rPDK4 promoter.
A gel shift mobility assay was conducted as described in the experimental procedures
section using the oligomers for the potential TRE1 site and its mutated version. The
sequences for these oligomers are given below the gel shift with the mutated nucleotides
shown in bold, and the sequence for the wild type TRE is underlined.
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Figure 3.3: TRβ, C/EBPβ and PGC-1α are associated with the rPDK4 gene
promoter in vivo.
A. Chromatin immunoprecipitation assays (ChIP) were conducted on primary rat
hepatocytes. Hepatocytes were treated with 100nM thyroid hormone (T3) for 24 hours
and then crossed linked with 1% formaldehyde as described in materials and methods.
Antibodies to A. TRβ, B. PGC-1α and C. C/EBPβ, or immunoglobin G (IgG) were used
for immunoprecipitations. The amplified PCR products using primers for the proximal,
The PDK4-TRE and upstream region of the rPDK4 gene were resolved on an agrose gel.
D. The association of TRβ, C/EBPβ and PGC-1α with PDK4-TRE and proximal were
quantified using quantity one software. These data are the average ± SE of four
independent ChIP assays (** = p value 0.001 to 0.01).
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gene promoter but none of them were detected at the upstream control region of the
PDK4 promoter. The data indicate that T3 through TRβ, C/EBPβ and PGC-1α can
regulate the PDK4 transcription. This regulation may involve a looping of the proximal
region of the promoter with its distal region that contains the TRE site.
3.1.3 Thyroid hormone treatment increases the mRNA of both the PDK4 and PGC1α genes in primary rat hepatocytes.
I examined the effect of thyroid hormone (T3) on the abundance of both PGC-1α
and PDK4 mRNA in primary rat hepatocytes. Primary rat hepatocytes were treated with
T3 for 24 h and then RNA was isolated. The mRNA abundance was measured by real
time PCR. Both the PGC-1α and the PDK4 mRNA abundance were significantly
increased 2.6 ± 0.7 fold and 2.2 ± 0.3 fold after T3 treatment in rat hepatocytes,
respectively (Figure 3.4A). These data indicate that T3 can increase PGC-1α mRNA
abundance in the liver. However, previous studies from our laboratory showed that PGC1α mRNA abundance did not change in heart after T3 treatment suggesting that T3
induces PGC-1α in a tissue-specific manner (Zhang et al., 2004b). Next, I tested whether
PGC-1α and PDK4 protein abundance were increased in response to T3 administration in
rat hepatocytes. Using Western analyses to assess PGC-1α levels, we found that the PGC1α and the PDK4 protein abundance were increased 2.2 ± 0.2 fold and 2 ± 0.2 fold in
response to T3 treatment, respectively (Figure 3.4B). These experiments provide further
confirmation that the PGC-1α is a T3-responsive gene and supports our hypothesis that
PGC-1α is a coactivator in T3 action for the PDK4 gene.
3.1.4 PGC-1α enhances the thyroid hormone induction of the PDK4 gene and the
role of the forkhead transcription factor (FOXO1) and the estrogen related receptor
α (ERRα) in this enhancement.
In the next experiments I examined the ability of PGC-1α to enhance the T3
induction of the PDK4 gene. I conducted co-transfections of pSV-PGC-1α with the wild
type -1256/+78 rPDK4-luc or the forkhead transcription factor (FOXO1) mutant at
position -347 or the estrogen related receptor α (ERRα) mutants at positions -338 and 370 of the -1256/+78 rPDK4-luc. Transfections were conducted in HepG2 hepatoma
cells. Primers used to establish the mutations in the -1256/+78 rPDK4-luc are listed in the
experimental procedures section. Addition of 100nM of T3 for 24 hours stimulated the
wild type version of -1256/+78 rPDK4-luc vector by 8.4 ± 2 fold. In these experiments,
overexpression of PGC-1α induced it by 4.3 ± 0.7 fold. When T3 was added in the
presence of PGC-1α, I obtained a synergistic effect with 23.2 ± 4 fold induction. Also,
when treating the -338 ERRα mutant, -370 ERRα mutant and -347 FOXO1 mutant
versions of the rPDK4 -1256/+78 with T3 all of them showed luciferase induction by
similar levels 7 ± 1.2 fold, 6.1 ± 1.3 fold and 7.1 ± 0.7 fold, respectively. However, the
overexpression of PGC-1α did not induce either of the ERRα mutants or induced the -347
FOXO1 mutant by 3.1 ± 0.6 fold only, which is still lower than the wild type -1256/+78
induction.
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Figure 3.4: Thyroid hormone increases PDK4 and PGC-1α mRNA and protein
abundance in primary hepatocytes.
A. Primary rat hepatocytes were plated on collagen-coated plates for 16 h. T3 was added
at a concentration of 100 nM to the hepatocytes for 24 h. RNA was harvested, and the
abundance of PDK4 and PGC-1α mRNA was determined by real time PCR. The data are
presented as the fold induction of mRNA abundance by T3 (average ± SE) from four
independent hepatocytes preparations, and the control samples were assigned a relative
value of 1. B. The expression of the PDK4 and PGC-1α proteins was monitored by
Western blot analysis using specific antibodies (1: 1000, Santa Cruz). The data are
presented as the fold induction of protein abundance by T3 (average ± SE) from three
independent hepatocytes preparations, and the control samples were assigned a relative
value of 1 (* = p value 0.01 to 0.05, ** = p value 0.001 to 0.01).
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But astonishing, when T3 was added in the presence of PGC-1α, I still obtained a
significant synergistic effect for all the mutants versions of the -1256/+78 as follows:
15.5 ± 3.5 fold for the -338 ERRα mutant, 11.6 ± 2 fold for the -370 ERRα mutant and
20.1 ± 4.4 fold for the -347 FOXO1 mutant (Figure 3.5). These data indicate that PGC1α stimulates PDK4 gene primarily through the -338 to -370 region of the rPDK4
promoter but, more importantly, that PGC-1α can act as a coactivator for the T3 induction
of the PDK4 gene either through binding to its elements in the -338 to -370 region or may
be through interacting with the thyroid receptor itself. For this reason we still observed a
significant synergistic effect with T3 addition even though I mutated both ERRα sites in
the promoter and PGC-1α alone by itself could not induce the PDK4 promoter.
Supporting this concept are the ChIP data showing association of PGC-1α with the
rPDK4 TRE site Figure 3.3D. Moreover, previous studies had detected an interaction
between the PGC-1α and both the TRβ and RXR in vitro and in vivo (Delerive et al.,
2002; Puigserver et al., 1998; Wu et al., 2002). To further confirm this possibility I used
adenoviral delivery of shRNA specific for silencing the PGC-1α in primary hepatocytes
to see the effect of reduction in the PGC-1α gene expression on the hepatic T3 induction
of PDK4 gene as.
3.1.5 Knocking down of the PGC-1α in rat primary hepatocytes affects the ability of
thyroid hormone to induce different metabolic genes.
To test the role of the PGC-1α in the T3 induction of hepatic metabolic gene
expression, I infected rat primary hepatocytes with adenovirus encoding the shRNA to
silence the PGC-1α (Ad-siPGC-1α) for 16 hours prior to treatment of cells with T3 for
additional 24 hours. Adenovirus encoding control shRNA that does not silence any rat
genes was used as a control (Ad-NC). Ad-siPGC-1α significantly knocked down the
expression of PGC-1α by 70% compared to the Ad-NC in hepatocytes non-treated with
T3 (0.3 ± 0.04 fold relative to Ad-NC infected hepatocytes non treated with T3). In
addition, the induction of PGC-1α by T3 treatment was reduced in hepatocytes infected
with Ad-siPGC-1α (0.6 ±0.04 fold relative to Ad-NC infected hepatocytes untreated with
T3) in comparison to that infected with Ad-NC (6.2 ± 3 relative to Ad-NC infected
hepatocytes untreated with T3) (Figure 3.6A). The knock down of the PGC-1α in
primary hepatocytes was accompanied by inability of T3 to induced the expression of
PDK4, CPT-1a, PEPCK and C/EBPβ, while T3 had increased all these genes in
hepatocytes infected with Ad-NC by 3.3 ± 0.9 fold, 3.9 ± 1 fold, 3.12 ± 0.52 fold, 1.7 ±
0.35 fold, respectively (Figure 3.6B-E). This impairment of the T3 induction for these
metabolic genes after PGC-1α silencing indicates that PGC-1α is an important
coactivator in the T3 induction process of these genes in primary hepatocytes.
I have shown in this first part of the results chapter of this dissertation the ability
of thyroid hormone to induce the PDK4 gene through a TRE and that PGC-1α enhanced
this induction. When PGC-1α was completely silenced, thyroid hormone lost its ability to
activate the PDK4 gene indicating that PGC-1α is an important coactivator in this
process.
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Figure 3.5: PGC-1α enhances the T3 induction of rPDK4 gene.
HepG2 hepatoma cells were transiently transfected with 2 µg of different rPDK4-Luc
constructs, 1 µg of pSV-PGC-1α or pSV, 1.0 µg of RSV-TRβ, and 0.1 µg of TK-Renilla.
T3 was added at a concentration of 100 nM for 24 h. All transfections were performed in
duplicate and repeated three to six times. Luciferase and renilla assays were performed in
the same tube. Luciferase activity was corrected for both protein content and renilla
activity which served as a transfection control. Results are expressed as fold induction by
PGC-1α or T3 compared to the untreated cells in each data set (* = p value 0.01 to 0.05,
** = p value 0.001 to 0.01, *** = p value <0.001).
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Exon 1

Figure 3.6: The effect of knocking down the PGC-1α on the induction gene
expression of the PDK4, CPT-1a, PEPCK and C/EBPβ by T3.
Rat primary hepatocytes were infected with adenoviral vectors expressing shRNA for
PGC-1α (Ad-siPGC-1α), or expressing control-shRNA (Ad-NC). After 24 h, hepatocytes
were treated with T3 at a concentration of 100nM for another 24 hours. RNA was
isolated from the cells, and the mRNA abundance of the indicated genes was measured
by real time PCR. 18S rRNA was used as the control. The infections were repeated three
times on independent plates of cells. A. fold induction of the PGC-1α gene expression in
hepatocytes in comparison to hepatocytes infected with Ad-NC and non-tretaed with T3.
B. PDK4, C. CPT-1a, D. PEPCK and E. C/EBPβ mRNAs abundance were also measured
in the same time with measuring the PGC-1α gene expression. The data are expressed as
the mean of the fold induction ± S.E. of mRNA abundance relative to cells non-treated
with T3 (* = p value 0.01 to 0.05, ** = p value 0.001 to 0.01).
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Figure 3.6: (continued).
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Figure 3.6: (continued).
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To further investigate the mechanism of PDK4 induction by thyroid hormone, I
tested the role of another coregulator, C/EBPβ, that was associated with the PDK4 gene
promoter by ChIP technique in the induction of PDK4 by thyroid hormone (refer to
Figure 3.3C).
3.1.6 Overexpression of C/EBPβ induces the rPDK4 gene luciferase promoter.
Previous studies from our laboratory had shown that C/EBPβ is implicated in the
T3 induction of the PEPCK gene (Park et al., 1999). Therefore, in the following part of
this dissertation I investigated the role of the C/EBPβ as a coregulator in the induction of
the PDK4 gene by T3. In the first experiment, I tested the ability of the C/EBPβ to induce
the PDK4 gene promoter in the absence of T3. I conducted co-transfections of different
serial deletions constructs of the rPDK4 promoter driving a luciferase reporter and MSVC/EBPβ in HepG2 hepatoma cells and measured the level of induction for these
luciferase constructs. Luciferase assays showed that deletion of the 210 nucleotides
between -788 to -578 of the rPDK4 promoter significantly reduced C/EBPβ
responsiveness from 7.6 ± 0.7 fold to 3.3 ± 0.5 fold (p= 0.001), and also the deletion of
the 255 nucleotides between -325 to -70 of the rPDK4 promoter significantly reduced
C/EBPβ responsiveness from 4.4 ± 0.8 fold to 1.00 ± 0.3 fold (p= 0.005) (Figure 3.7).
These data indicate that C/EBPβ can induce PDK4 gene expression and that at least two
sites in the PDK4 gene promoter between nucleotides -788 to -578 and -325 to -70 are
essential for its action. These data are consistent with the ChIP data (Figure 3.3C) where
C/EBPβ was associated with both the proximal and the TRE site of rPDK4 gene
promoter.
3.1.7 Thyroid hormone treatment increases the C/EBPβ protein abundance in
primary hepatocytes.
The next question investigated whether C/EBPβ was regulated by T3. I treated
primary rat hepatocytes with 100nM T3 for 24 h and extracted proteins. Using Western
analyses to assess C/EBPβ protein level, I found that the C/EBPβ protein abundance was
significantly increased by 2.1 ± 0.4 fold in response to T3 treatment (Figure 3.8). This
experiment demonstrated that C/EBPβ abundance is modulated by T3 and raised the
possibility that it may be a coregulator in T3 action for the PDK4 gene.
3.1.8 C/EBPβ enhances the thyroid hormone induction of rPDK4 gene.
In the next experiment, I examined the ability of the C/EBPβ to enhance the T3
induction of the PDK4 gene. I conducted co-transfections of the wild type -1256/+78
rPDK4-luc and MSV-C/EBPβ in HepG2 hepatoma cells with and without T3 addition.
Addition of 100nM of T3 for 24 hours stimulated the wild type version of -1256/+78
rPDK4-luc vector by 5.3 ± 1.1 fold. In these experiments, overexpression of C/EBPβ
induced the PDK4-luc vector 4.7 ± 1.3 fold.
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Figure 3.7: Overexpression of C/EBPβ induces the rPDK4 promoter.
HepG2 cells were transiently transfected with 2 µg of different rPDK4 constructs, 1 µg of
MSV-C/EBPβ, and 0.1 µg of TK-renilla. All transfections were performed in duplicate
and repeated three at least three times. Luciferase and renilla assays were performed in
the same tube. Luciferase activity was corrected for both protein content and renilla
activity which served as a transfection control. Results are expressed as the relative
induction by T3 ± S.E by comparing the T3 induction of vectors in the treated cells to the
non-treated ones. The significance is calculated in relative to the shortest version of the
rPDK4-luciferase (-70/+78) (** = p value 0.001 to 0.01, *** = p value <0.001).
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Figure 3.8: Thyroid hormone increases the C/EBPβ protein abundance in primary
hepatocytes.
The expression of the C/EBPβ proteins was monitored by Western blot analysis using
specific antibodies (1: 1000, Santa Cruz). The data are presented as the fold induction of
protein abundance by T3 (average ± SE) from three independent hepatocytes
preparations, and the control samples were assigned a relative value of 1 (* = p value
0.01 to 0.05).
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When T3 was added in the presence of C/EBPβ, I obtained a significant
synergistic effect with a 16.9 ± 5 fold induction (Figure 3.9). These data indicate that
C/EBPβ can activate the PDK4 gene promoter and can act synergistically with the T3 to
amplify its effect on the PDK4 gene promoter.
To further demonstrate and confirm the role of the C/EBPβ protein in the
induction of PDK4 transcription, I tested a set of specific dominant negative vectors.
Hep4-C/EBP is a dominant negative C/EBP vector, which has the C/EBP leucine zipper
attached to an acidic amphipathic helix containing 4 heptads repeats (Krylov et al., 1995).
The amphipathic helix interacts with the basic region of C/EBP proteins to form a strong
non-DNA binding heterodimer and inhibits all C/EBP proteins including both alpha and
beta isoforms (Krylov et al., 1995). For controls, I used the hep4-CREB which is a
dominant negative CREB protein with a CREB leucine zipper and an amphipathic helix
(Ahn et al., 1998) and the hep4-Fos which is a dominant negative Jun vector with the Fos
leucine zipper and an amphipathic helix (Olive et al., 1997). To examine the effect of
these dominant negative proteins on the basal induction of the PDK4 gene, the -1256/+78
PDK4-luc vector was cotransfected with three dominant negative vectors into HepG2
cells and after 48 hours from the transfection, proteins were extracted from the cells and
tested for the luciferase level induction. The dominant negative C/EBP reduced the basal
levels of the PDK4 gene significantly by 32% (p= 0.02), while the dominant negative
FOS did not have any effect on the basal level of the PDK4 gene and the dominant
negative CREB even significantly doubled its basal level (p= 0.0007) (Figure 3.10A).
The reason for the induction of the PDK4 gene basal level by hep4-CREB is not known.
To confirm the role of the C/EBP proteins in the induction of the PDK4 gene by
T3, I cotransfected the -1256/+78 PDK4-luc vector with three dominant negative vectors
into HepG2 cells and treated them with 100nM T3. Proteins were extracted from the cells
and tested for the luciferase activity. Cotransfection with hep4-C/EBP inhibited the 4.5 ±
1.3 fold induction of T3. Both the dominant negative CREB and FOS did not affect at all
the induction by T3 (Figure 3.10B).
These data indicate that C/EBPβ induces the expression of the PDK4 gene and
enhances the T3 induction of this gene. Inhibition of the C/EBP isoforms by dominant
negative vectors abolishes the ability of T3 to induce PDK4 gene. However, the dominant
negative vectors cannot differentiate between the two isoforms of the C/EBP and
therefore, to pinpoint which isoform this involved in the T3 induction of the PDK4 gene,
I used adenoviral shRNA delivery to specifically inhibit the C/EBPβ isoform in the
primary rat hepatocytes.
3.1.9 Knocking down C/EBPβ reduces the ability of thyroid hormone to induce
PDK4 gene expression in primary rat hepatocytes.
To test the role of the C/EBPβ in the T3 induction of PDK4 gene expression, I
infected rat primary hepatocytes with adenovirus encoding the shRNA to silence
specifically the C/EBPβ (Ad-siC/EBPβ).
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Figure 3.9: C/EBPβ enhances the T3 induction of the rPDK4 gene.
HepG2 hepatoma cells were transiently transfected with 2 µg of -1256/+78 rPDK4-Luc
constructs, 1 µg of MSV-C/EBPβ or MSV, 1.0 µg of RSV-TRβ, and 0.1 µg of TKRenilla. T3 was added at a concentration of 100 nM for 24 h. All transfections were
performed in duplicate and repeated three times. Luciferase assays were performed as
described in Figure 3.8. Results are expressed as fold induction by PGC-1α or T3 versus
the untreated cells in each data set (* = p value 0.01 to 0.05, ** = p value 0.001 to 0.01).

42

Figure 3.10: The effect of inhibiting the C/EBP, FOS and CREB on the induction of
rPDK4 by T3.
A. The effect of inhibiting the C/EBP, FOS and CREB on the basal expression of the 1256/+78 rPDK4 luc. HepG2 hepatoma cells were transiently transfected with 2 µg of 1256/+78 rPDK4-Luc constructs, 1 µg of PSV-40, hep4-C/EBP, hep4-FOS or hep4CREB, 1.0 µg of RSV-TRβ, and 0.1 µg of TK-Renilla. Fourty-eight hours after the
transfection, cells were collected. All transfections were performed in duplicate and
repeated three times. Luciferase and renilla assays were performed in the same tube.
Luciferase activity was corrected for both protein content and renilla activity which
served as a transfection control. Results are expressed as fold induction by PGC-1α or T3
versus the untreated cells in each data set (* = p value 0.01 to 0.05, *** = p value
<0.001). B. The effect of inhibiting the C/EBP, FOS and CREB on the induction of the 1256/+78 rPDK4 luc by T3. HepG2 hepatoma cells were transiently transfected with 2
µg of -1256/+78 rPDK4-Luc constructs, 1 µg of PSV-40, hep4-C/EBP, hep4-FOS or
hep4-CREB, 1.0 µg of RSV-TRβ, and 0.1 µg of TK-Renilla. T3 was added at a
concentration of 100 nM for 24 h. All transfections were performed in duplicate and
repeated three times. Luciferase assays were performed as described above. Results are
expressed as fold induction by PGC-1α or T3 versus the untreated cells in each data set (*
= p value 0.01 to 0.05, ** = p value 0.001 to 0.01).
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Hepatocytes were transduced with the adenoviruses for 16 hours prior to
treatment of cells with T3 for another 24 hours. Adenovirus encoding control shRNA that
does not silence any rat genes was used as a control (Ad-control). I obtained these
adenoviruses from Dr. Jacob E. Friedman from University of Colorado at Denver
(Schroeder-Gloeckler et al., 2007). Ad-siC/EBPβ significantly knocked down the
expression of C/EBPβ by 65% compared to the Ad-NC in hepatocytes untreated with T3
(0.4 ± 0.02 fold relative to Ad-control infected hepatocytes untreated with T3). In
addition, the induction of C/EBPβ by T3 was reduced in hepatocytes infected with AdsiC/EBPβ (0.4 ± 0.04 fold relative to Ad-control infected hepatocytes untreated with T3)
in comparison to that infected with Ad-control (1.8 ± 0.3 relative to Ad-control infected
hepatocytes untreated with T3) (Figure 3.11A). The knock down of the C/EBPβ in
primary hepatocytes was accompanied by a significant reduction in the T3 induction of
PDK4, as T3 induced PDK4 only by 1.55 ± 0.24 fold while T3 had increased PDK4 in
hepatocytes infected with Ad-control by 2.3 ± 0.2 fold (Figure 3.11B). This reduction of
the T3 induction for the PDK4 gene expression after C/EBPβ silencing indicates that
C/EBPβ is an important coregulator in the T3 induction process of the PDK4 gene
expression in primary hepatocytes.
From the previous experiments, I have confirmed the induction of PDK4 gene by
T3 treatment. I also showed that both the PGC-1α and C/EBPβ are important coregulators
for this induction. However, previous studies had shown that thyroid hormone induces a
number of metabolic genes. This implies a large network of genes and transcription
factors that are involved in the T3 cellular and genomic actions (Weitzel et al., 2001; Yen
et al., 2006). Therefore, I designed the next experiment to identify the early response
network of transcription factors and metabolic genes that are regulated following 24
hours of T3 treatment involved in the thyroid hormone metabolic action.
3.1.10 Thyroid hormone treatment induces a network of transcription factors and
different metabolic genes in primary rat hepatocytes.
Thyroid hormone regulates the expression of key metabolic genes including
phosphoenolpyruvate carboxykinase (PEPCK), carnitine palmitoyltransferase 1a (CPT1a), apolipoprotein B (ApoB) and uncoupling protein 3 (UCP3) (Boss et al., 2000;
Jackson-Hayes et al., 2003; Mukhopadhyay et al., 2003; Park et al., 1997; Yen et al.,
2006). Also, previous studies demonstrated that T3 elevates the abundance of many
transcription factors and coactivators associated with mitochondrial biogenesis and lipid
metabolism, such as PGC-1α and ERRα (Xie et al., 1999; Zhang et al., 2004b). These
facts indicate that T3 may stimulate metabolism in part by increasing a network of
transcription factors that induce different metabolic genes which may or may not contain
a TRE site within their promoters. To address this possibility, I treated primary rat
heptocytes with 100nM T3 for 24 hours, and then RNA was isolated from these
hepatocytes and from non-treated ones. RNA was assessed on a superarray, containing
90 real time PCR primers for genes of transcription factors and metabolic genes,
according to the manufacturer procedures using the Roche Light cycler 480 machine. A
complete list of these genes is provided in the experimental procedures section.
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Figure 3.11: The effect of knocking down the C/EBPβ on the induction gene
expression of the PDK4 gene by T3.
Rat primary hepatocytes were infected with adenoviral vectors expressing shRNA for
C/EBPβ (Ad-siC/EBPβ) or expressing control-shRNA (Ad-control). After 24 h,
hepatocytes were treated with T3 at a concentration 100nM for another 24 hours. RNA
was isolated from the cells, and the A. PDK4 and B. C/EBPβ mRNA abundance was
measured by real time PCR. 18 S rRNA was used as the control. The infections were
repeated four to seven times on independent plates of cells. The data are expressed as the
mean of the fold induction ± S.E. of mRNA abundance relative to cells non-treated with
T3.
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The results from four independent hepatocytes preparations showed up-regulation
of 27 genes by more than 1.5 fold relative to non-treated cells (Figure 3.12). Thyroid
treatment significantly induced genes involved in glucose homeostasis and
gluconeogenesis such as, glucose-6-phosphatase (G6pase) by 1.7 ± 0.2 fold,
phosphoenolpyruvate carboxykinase (PEPCK) by 3.7 ± 1.1 fold, solute carrier family 2
(facilitated glucose transporter), member 4 (Slc2a4) by 3.2 ± 0.6 fold, cytochrome P450
2E1 (Cyp2e1) by 2.2 ± 0.7 fold (Lieber, 1999). On the other hand, T3 treatment induced
genes involved in fatty acid oxidation and metabolism such as, 3-ketoacyl-Coenzyme A
thiolase alpha subunit (Hadha) by 2.5 ± 0.05 fold, fatty acid binding protein 3/small
heterodimer partner (Fabp3/SHP) by 2.5 ± 0.8 fold, solute carrier family 25
carnitine/acylcarnitine translocase member 20 (Slc25a20) by 2 ± 0.5 fold, fatty acid
binding protein 1 (Fabp1) by 2.7 ± 1 fold, carnitine palmitoyltransferase 1a (CPT-1a) by
2 ± 0.6 fold, and acetyl-Coenzyme A carboxylase beta (Acacb) by 2.6 ± 0.8 fold.
Interestingly T3 significantly induced genes involved in fatty acid and lipid synthesis
including, solute carrier family 27 fatty acid transporter member 5 (Slc27a5) by 1.9 ± 0.3
fold, fatty acid synthase (FAS) by 2.3 ± 0.3 fold.
Also, T3 treatment induced number of transcription factors such as, GA binding
protein transcription factor, beta subunit 1 (Gabpb1) by 1.9 ± 0.4 fold, peroxisome
proliferative activated receptor, delta (Pparδ) by 3.1 ± 1 fold, estrogen related receptor
gamma (EsRRγ) by 2.5 ± 0.9, CCAAT/enhancer binding protein beta (C/EBPβ) by 2 ±
0.7, sterol regulatory element-binding transcription factor 1 (Srebf1) by 3.5 ± 0.6 (Zhang
et al., 2003), Sirtuin 1 (Sirt-1) which deacetylates proteins that contribute to cellular
regulation (Frye, 1999), and the homeobox protein NK-2 homolog (Nkx2.5) that binds
and activates the promoter of thyroid specific genes such as thyroglobulin,
thyroperoxidase, and thyrotropin receptor (Civitareale et al., 1989; Dentice et al., 2006;
Francis-Lang et al., 1992), it was increased by 2.8 ± 0.7 fold. In addition, T3 treatment
showed induction of number of transcription coactivators such as, peroxisome
proliferative activated receptor gamma coactivator-1 alpha (PGC-1α) by 2.3 ± 0.9 fold,
peroxisome proliferative activated receptor gamma coactivator-1 beta (PGC-1β) by 3 ±
1.1 fold, also T3 induced both lipin gene isoforms, 1 and 2, by 2.1 ± 0.7 and 3.6 ± 1.6
fold, respectively.
Finally T3 treatment induced number of miscellaneous proteins involved in
different metabolic processes including, deiodinase, iodothyronine, type II (Dio2) which
is responsible for the activation of thyroid hormone by converting the prohormone
thyroxine (T4) by outer ring deiodination (ORD) to bioactive triiodothyronine (T3)
(Yen, 2001), it was increased by 3.7 ± 1 fold, pyruvate dehydrogenase kinase isoform 4
(PDK4) by 3 ± 0.7 fold and both isoforms of the uncoupling proteins, 2 and 3 (UCP2
and UCP3), involved in thermogensis, insulin secretion and fatty acid transportation
anions (Fisler & Warden, 2006), T3 induced UCP2 and UCP3 by 3.2 ± 1.5 fold and 3.5
± 1.6, respectively.
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Figure 3.12: Effect of T3 on transcription factor and metabolic gene abundance in
primary rat hepatocytes.
Primary rat hepatocytes were plated on collagen-coated plates for 16 h. T3 was added at a
concentration of 100 nM to the hepatocytes for 24 h. RNA was harvested using RNASTAT 60 and treated with Turbo DNase I to remove contaminating genomic DNA and
further purified using the Qiagen RNeasy kit. The extracted total RNA was converted
into cDNA using superarray RT2 First Strand Kit. The abundance of the transcription
factors and metabolic genes mRNA was determined by superarray® real time PCR (RT2
Profiler™ PCR Array System, SABiosciences cat # CAPR-0529F). This superarray
contains primers for 90 transcription factors/metabolic genes and 6 controls. The cDNA
was assessed on the superarray according to the manufacturer protocol with a Roche light
cycler 480. The data are presented as the fold induction of mRNA abundance by T3
(average ± SE) from four independent hepatocytes preparations and the control samples
were assigned a relative value of 1. Only the genes that were induced by T3 treatment by
more than 1.5 fold relative to non-treated cells are represented in this figure (* = p value
0.01 to 0.05, ** = p value 0.001 to 0.01, *** = p value <0.001).
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3.2 Experimental procedures
3.2.1 Transient transfection of luciferase vectors
PDK4-luciferase constructs (PDK4-luc) were transiently transfected into HepG2
cells by the calcium phosphate method as previously described (Zhang et al., 2004b).
Transfections included 2 µg of PDK4-luciferase along with SV40-thyroid hormone
receptor β (SV40-TRβ), PSV-PGC-1α and TK-Renilla. For experiments with C/EBPβ;
MSV-C/EBPβ was included in the transfection. Dominant negative vectors for C/EBP
(hep4-CEBP), CREB (hep4-CREB) and FOS (hep4-FOS) were also transfected. Cells
were transfected in Dulbecco's modified Eagle's medium containing 5% calf serum, 5%
fetal calf serum and incubated overnight at 37 °C. Following two washes with phosphatebuffered saline, the medium was replaced by Dulbecco's modified Eagle's medium
containing no serum. Cells were treated with 100 nM T3 for 24 h. After T3 treatment,
cells were lysed in Passive Lysis Buffer (Promega). Both luciferase and Renilla activity
were measured using Promega dual luciferase reporter kit (cat# E1980). Protein content
in each lysate was determined by Pierce BCA Protein assay kit (cat# 23225). Luciferase
activity was corrected for both protein content and Renilla activity to account for cell
density and transfection efficiency, respectively.
3.2.2 Site directed mutagenesis of the rPDK4 promoter
Stratagene’s Quick-change-XL site directed mutagenesis kit was used to carry out
mutation in the potential TREs in the -1256/+78 rPDK4-luciferase vector. TRE1 was
disrupted by changing the (GGT) in its second hexamer half site sequence into (AAC),
while the TRE2 was disrupted by changing only two nucleotides (GG) in its second
hexamer half site into (AA). In addition, site directed mutagenesis technique was used to
carry out mutations in the ERRα and FOXO1 binding sites in the -1256/+78 rPDK4luciferase vector. Mutations of the ERRα binding site are named Mut338 and Mut370,
while the mutation of the FOXO1 binding site is named Mut347. Primers used to
establish all these mutations are listed in Table 3.1, mutated nucleotides are in bold.
3.2.3 In vivo luciferase transfection
In vivo transfection of the wild type and mutated TRE1 -1256/+78 was done by
electroporation in hypothyroid (by hypophysectomy) rats livers. Four hypothyroid rats
were used without thyroid treatment and another 4 rats were treated with T3 three days
prior to electroporation, with an additional half-dose injection the day before
electroporation. This experiement was done in Dr. Gene Ness lab in University of South
Florida. Electroporation was performed as previously described (Lagor et al., 2007).
Approximately 16 µg of plasmid in 40 µl of sterile saline was subcaspsular injected using
a 30-gauge, 3/8-in length needle and it was visible below the capsular surface as a
blanched out area after injection. A circular six-node electrode was placed on the liver
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Table 3.1: Sequences of the primers used for the site-directed mutagenesis of the
rPDK4 promoter.
TRE region

Primer sequence

MutTRE1
Forward

5'-GAGGGCTAAGGGCACCTTGAACAACAAACTGCCTTTGCTGC-3'

MutTRE1
Reverse

5'-CTCCCGATTCCCGTGGAACTTGTTGTTTGACGGAAACGACG-3'

MutTRE2
Forward

5'-GAGTGAACAGAAGAGCGAGAGAAATTAGGATGAGAGTTTTATGAC-3'

MutTRE2
Reverse

5'-CTCACTTGTCTTCTCGCTCTCTTTAATCCTACTCTCAAAATACTG-3'

Mut338
Forward

5'-AGATGGCTCCTGAGTTGTAAACAAAAACAAGTCTGGGCGGG-3'

Mut338
Reverse

5'-CCCGCCCAGACTTGTTTTTGTTTACAACTCAGGAGCCATCT-3'

Mut347
forward

5'-TGACATTGAGATGGCTCCTGAGTTTGCAACAAGGACAAGTCTGGGC-3'

Mut347
Reverse

5'-GCCCAGACTTGTCCTTGTTGCAAACTCAGGAGCCATCTCAATGTCA-3'

Mut370
forward

5'-CAGTTTCTGGCGAGGAATGCGTGTTCGTGAGATGGCTCCTGAGTTGTAA-3'

Mut370
Reverse

5'-TTACAACTCAGGAGCCATCTCACGAACACGCATTCCTCGCCAGAAACTG-3'
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area where the plasmid was visible, so that each rat liver was electroportaed with both the
wild type and the mutated version of the -1256/+78 plasmid, in different spots of the
liver. Electrodes were sunk to a controlled depth of 2 mm using a rubber spacer. 6 x 150msec pulses at 100 V/cm, with a 150-msec rest between pulses were used to perform the
transfection for optimal gene delivery to the liver with minimal tissue damage. To control
for transfection efficiency, a plasmid-encoding renilla luciferase was cotransfected. After
electroporation, the liver was placed back in the abdomen, and the wound was closed
with surgical staples. At the time of surgery, animals were given a single subcutaneous
injection of ketoprofen (5 mg/kg) for analgesia.
The results are expressed as the mean of luciferase activity of the wild type 1256/+78 rPDK4-luciferase to that of the TRE1 mutated -1256/+78-luciferase for the
hypothyroid rats or T3-treated rats.
3.2.4 Electrophoretic mobility shift
Electrophoretic mobility shift assays were conducted by labeling double-stranded
oligonucleotides with Klenow enzyme and [α-32P]dCTP. Oligonucleotides were designed
that contain sequences for the TRE1. The mutated oligomers for each site (See Figure
3.2 for oligomer sequences) are identical to the mutations introduced into the PDK4-luc
by site directed mutagenesis. His-tagged TRβ and RXR proteins were used to determine
the ability of binding the TRβ-RXR complex to bind to either the wild type or the
muataed oligos (Bahouth et al., 1997; Park et al., 1997). The protein-DNA binding
mixtures contained labeled probe (30,000 cpm) and the purified protein in 80 mM KCl,
25 mM Tris-HCl (pH 7.4), 0.1 mM EDTA, 1 mM dithiothreitol, 10% glycerol and poly
deoxyinosine-deoxycytidine; which is a nonspecific competitor. The binding reactions
was incubated at room temperature for 20 min and then resolved on 5% non-denaturing
acrylamide gels (80:1, acrylamide/bisacrylamide) in Tris-glycine running buffer (22 mM
Tris and 190 mM glycine). The electrophoresis was carried out at 180 volts for 80 min at
4 °C.
3.2.5 Chromatin immunoprecipitation (ChIP) assay
The ChIP assays were performed as follows. Rat primary hepatocytes were
prepared extracted from rat liver tissues by collagenase perfusion as previously described
(Deng et al., 2002). Rat primary hepatocytes (3 x 106 in 60-mm dishes) were maintained
for 12 h in priming media of RPMI 1640 and 10% fetal bovine serum. Following two
washes with phosphate-buffered saline, the medium was replaced by RPMI 1640 medium
containing no serum. Then cells were treated with 100 nM T3 for 24 h. Cross-linking was
performed with 1% formaldehyde for 15 min at room temperature and stopped by adding
125 mM glycine to each plate for 5 min. Cross-linked hepatocytes were washed twice
with ice-cold phosphate-buffered saline. Cells were scraped from the plate and collected
by centrifuging for 5 min at 2,000 rpm. ChIP assays were conducted with slight
modifications following the protocol given by the Millipore Magna
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ChIP kit (#17-610). The cell pellets were resuspended in 200 µl of cell lysis buffer,
containing protease inhibitor mixtures (P8340, Sigma). Samples were incubated on ice
for 15 min and vortexed once, followed by homogenization using a Dounce homogenizer.
The homogenate was pelleted, resuspended in nuclear lysis buffer, and
sonicated to 400-600bp 9 x 30 seconds in ice water, followed by centrifugation at 14,000
rpm for 10 min. Chromatin preparations were diluted with dilution buffer and protease
inhibitor cocktail and designated as input samples (no antibody), used for
immunoprecipitation with the desired antibody, or with the control antibody rabbit IgG
(Santa Cruz # sc-2027). Antibodies used were anti-TRβ (sc-67122, Santa Cruz
Biotechnology), anti-PGC-1α (sc-13067, Santa Cruz Biotechnology.), or anti-C/EBPβ
(sc-150, Santa Cruz Biotechnology). Samples were left rotating overnight at 4º with the
antibody and the A magnetic beads. The magnetic beads were pelleted and washed with a
low-salt immune complex wash buffer, high-salt immune complex wash buffer, lithiumchloride immune complex wash buffer, and TE buffer. DNA was eluted using the ChIP
elution buffer and treated with proteinase K for 4 hours at 65ºC followed by 10
minutes at 95 ºC. DNA was purified using the Qiaquick PCR purification kit
(Qiagen, #28104).
A total of 3–6 µl of purified sample was used in 35 cycles of PCR. Primers for
regions of the target genes are listed in Table 3.2. The PCR products were analyzed on
2% Nusieve 3:1 agarose (Cambrex, 50094) and visualized with MultiImage Light
Cabinet with Alpha Imager EP software. The relative intensity of the bands was
determined using AlphaView version 1.2.0.1 (Alpha Innotech Corporation).
3.2.6 Real-time PCR
For real time PCR, cDNA was prepared using RNA isolated from primary rat
hepatocytes. The RNA was isolated with RNA-Stat-60 (Tel-test) (Zhang et al., 2006).
The RNA was then treated with DNase I (2 units) at 37 °C for 1 h followed by addition of
DNase Inactivation Reagent (Ambion). The concentration of each sample containing
DNA free RNA was measured using Nano drop machine (Thermo scientific). Equal
amounts of DNA-free RNA were used for first-strand cDNA synthesis. Two μg of
DNA-free RNA extracted from different cells was converted to cDNA using Superscript
reverse transcriptase III and random hexamers (Invitrogen). The parameters for real time
PCR were as follows: 95 °C for 10 min, 40 cycles of 95 °C 30 s and 60 °C 1 min. The
final concentration of primers in each well in the PCR plates was 0.1 μM. . Four μl of 1:5
of each cDNA was used as a template to assess target genes and the normalize control
18S gene. The following forward (FP) and reverse primers (RP) were used for real time
PCR to quanitate mRNA abundance: PDK4 forward primer, ggattactgaccgcctctttagtt;
PDK4
reverse
primer,
gcattccgtgaattgtccatc;
PGC-1α
forward
primer,
atgaatgcagcggtcttagc; PGC-1α reverse primer, aacaatggcagggtttgttc; CPT-1a forward
primer, cggttcaagaatggcatcatc; CPT-1a reverse primer, tcacacccaccaccacgat; 18S forward
primer, cggctaccacatccaaggaa; 18S reverse primer, ttttcgtcactacctccccg. While the
primers for both the C/EBPβ and the PEPCK were obtained from Qiagen (cat #
QT00366478 and QT01619975, respectively).
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Table 3.2: Sequences of the primers used in the ChIP assay to demonstrate
interactions of TRβ, PGC-1α and C/EBPβ with the PDK4 gene.
Regions of PDK4 gene
amplified

Forward primer (FP)

Reverse primer (RP)

rPDK4, -591/-338
(proximal)

TAAGGCTATTTAGGCAGTTT

CCAGACTTGTCCTTGTTTAC

rPDK4, -1535/-1228
(TRE site)

AGTGTCTCCACCAGATTGT

CTAAGAGAGCTAACCTAGT

rPDK4, -6634/-6377
(upstream)

TATGAGAAGTGCTGCAATAA CCAGACTTGTCCTTGTTTAC
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The results are relative quantification relates the PCR signal of the target
transcript in treated cells to that of the untreated control cells using the delta delta CT
method as described previously (Livak & Schmittgen, 2001).
3.2.7 Western blot
Western analysis was performed on whole cell extracts from non-treated primary
rat hepatocytes or treated with 100nM of T3 for 24 hours. Cells were lysed in RIPA
buffer (20 mM Tris-Cl, pH 7.4, 150 mM NaCl, 0.5% deoxycholate, 5 mM EDTA pH 8.0,
0.1% SDS, and diluted protease inhibitor mixture). The cells were vortexed for 1 minute.
The cell membranes was removed by centrifugation for 25 min at 4 °C. An equal amount
of protein was loaded onto a 12% SDS-PAGE gel and transferred to a 0.45-µm pure
nitrocellulose membrane (Bio-Rad). Blots were immunoblotted with primary antibodies
(anti-PGC-1α, anti-C/EBPβ and anti-PDK4) in phosphate-buffered saline containing 5%
nonfat dry milk powder and were incubated with horseradish peroxidase-conjugated antirabbit secondary antibody. Immunoreactive proteins were identified using Super Signal
West Femto Chemiluminescence Substrate (Pierce). The ChemiDocTM XRS gel
documentation system (Bio-Rad) was used to quantify the immunoreactive proteins.
Actin was used as the loading control for each lane.
3.2.8 Adenoviral infection
Purified adenoviruses encoding shRNA specific for the PGC-1α (Ad-siPGC-1α)
and control adenoviruses encoding non-template shRNA (Ad-NC) were amplified by
Viraquest incorporation. The purified adenoviruses encoding shRNA designed for
C/EBPβ targeting its 3'-untranslated region (5'-CCGGGCCCTGAGTAATCAC-3') were
obtained from Dr. Jacob E. Friedman from University of Colorado, together with its
control adenoviruses encoding non-template shRNA (Ad-control). Primary rat
hepatocytes were plated at a density of 3 x 106 in a 60-mm dish in RPMI 1640 media (3
plates for each condition). Five hours after plating the cells, media was aspirated and 2
ml of purified adenoviruses was added to the cells in the presence of 8ug/ml polybrene.
The media was changed 24 hours post transduction and the cells were treated with
100nM T3 for another 24 hours in serum free RPMI 1640. The hepatocytes were
harvested and RNA was isolated using RNA Stat 60 and converted to cDNA after DNase
treatment and real-time PCR was performed according to the instructions stated under the
real-time PCR section (see section 3.2.6).
3.2.9 Superarray® real time PCR
To investigate the role of T3 in the expression of different transcription factors,
superarray® real time PCR (SABioscience) was performed. The superarray is a custom
designed real time plate, containing primers for 90 transcription factors and 6 controls,
complete list of the genes is provided in Table 3.3. RNA was extracted from non-treated
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rat primary hepatocytes and hepatoctes treated with T3 100nM for 24 hours as mentioned
in section 3.2.6 Real-time PCR. The extracted RNA was converted to cDNA using first
strand synthesis kit from SABioscience, the produced cDNA was then assessed on the
superarray according to the manufacturer procedures using the Roche Light cycler 480
machine. The parameters for real time PCR were as follows: 95 °C for 10 min, 40 cycles
of 95 °C 15 s and 60 °C 1 min.

57

Table 3.3: Complete list of the genes primers on the superarray real time plate.
Gene name
1. Acyl-CoA synthetase long-chain family
member 1
2. Carnitine palmitoyltransferase 1a, liver
3. Carnitine palmitoyltransferase 1b, muscle
4. Carnitine palmitoyltransferase 1c
5. Carnitine acetyltransferase
6. Solute carrier family 25 (mitochondrial
carnitine/acylcarnitine translocase), member
20
7. Carnitine palmitoyltransferase 2
8. Acyl-Coenzyme A dehydrogenase, very
long chain
9. Acetyl-coenzyme A dehydrogenase,
medium chain
10. Cytochrome P450, family 2, subfamily e,
polypeptide 1
11. Malonyl-CoA decarboxylase
12. Acetyl-Coenzyme A carboxylase beta
13. Hydroxyacyl-Coenzyme A
dehydrogenase/3-ketoacyl-Coenzyme, alpha
subunit
14. Cd36 antigen
15. Solute carrier family 27 (fatty acid
transporter), member 1
16. Solute carrier family 27 (fatty acid
transporter), member 2
17. Solute carrier family 27 (fatty acid
transporter), member 4
18. Solute carrier family 27 (fatty acid
transporter), member 5
19. Solute carrier family 2 (facilitated glucose
transporter), member 2
20. Solute carrier family 2 (facilitated glucose
transporter), member 4
21. Hexokinase 2
22. Phosphoenolpyruvate carboxykinase 1
23. Glucose-6-phosphatase, catalytic
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Ref seq

Gene symbol

NM_012820

Acsl 1

NM_031559
NM_013200
XM_001075677
NM_001004085

Cpt1a
Cpt1b
Cpt1c
Crat

NM_053965

Slc25a20

NM_012930

Cpt2

NM_012891

Acadvl

NM_016986

Acadm

NM_031543

Cyp2e1

NM_053477
NM_053922

Mlycd
Acacb

NM_130826

Hadha

NM_031561

Cd36

NM_053580.2

Slc27a1

NM_031736.1

Slc27a2

XM_231115

Slc27a4

NM_024143

Slc27a5

NM_012879

Slc2a2

NM_012751

Slc2a4

NM_012735
NM_198780
NM_013098

Hk2
Pck1
G6pc

Table 3.3: (continued).
Gene name
24. Pyruvate dehydrogenase kinase,
isoenzyme 2
25. Pyruvate dehydrogenase kinase,
isoenzyme 4
26. Acetyl-coenzyme A acetyltransferase 1
27. 3-hydroxy-3-methylglutaryl-Coenzyme A
synthase 2
28. 3-hydroxy-3-methylglutaryl-Coenzyme A
lyase
29. 3-hydroxybutyrate dehydrogenase, type 1
30. 3-hydroxybutyrate dehydrogenase, type 2
(predicted)
31. Stearoyl-Coenzyme A desaturase 1
32. Fatty acid desaturase 2
33. Acyl-Coenzyme A oxidase 1, palmitoyl
34. Acyl-Coenzyme A oxidase 3, pristanoyl
35. Hydroxysteroid (17-beta) dehydrogenase 4
36. Acetyl-Coenzyme A acyltransferase 1
37. Alpha-methylacyl-CoA racemase
38. 2-4-dienoyl-Coenzyme A reductase 2,
peroxisomal
39. Acyl-CoA thioesterase 8
40. Phytanoyl-CoA hydroxylase
41. ATP-binding cassette, sub-family D (ALD),
member 1 (predicted)
42. Carnitine O-octanoyltransferase
43. ATP-binding cassette, sub-family D (ALD),
member 2
44. ATP-binding cassette, sub-family D (ALD),
member 3
45. Nuclear receptor subfamily 0, group B,
member 2
46. Apolipoprotein A-IV
47. Peroxisomal biogenesis factor 11A
48. Acyl-CoA thioesterase 12
49. Fatty acid synthase
50. Acetyl-coenzyme A carboxylase alpha
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Ref seq

Gene symbol

NM_030872

Pdk2

NM_053551

Pdk4

NM_017075

Acat1

NM_173094

Hmgcs2

NM_024386

Hmgcl

NM_053995

Bdh1

XM_215705

Bdh2

NM_139192
NM_031344
NM_017340
NM_053339
NM_024392
NM_012489
NM_012816

Scd1
Fads2
Acox1
Acox3
Hsd17b4
Acaa1
Amacr

NM_171996

Decr2

NM_130756
NM_053674

Acot8
Phyh

XM_343840

Abcd1

NM_031987

Crot

NM_033352

Abcd2

NM_012804

Abcd3

NM_057133

Nr0b2

NM_012737
NM_053487
NM_130747
NM_017332
NM_022193

Apoa4
Pex11a
Acot12
Fasn
Acaca

Table 3.3: (continued).
Gene name
51. Protein phosphatase 2C, magnesium
dependent, catalytic subunit
52. Pyruvate dehydrogenase phosphatase
isoenzyme 2
53. Fatty acid binding protein 1, liver
54. Fatty acid binding protein 3
55. Insulin receptor substrate 2
56. Thyroid hormone receptor alpha
57. Thyroid hormone receptor beta
58. Peroxisome proliferator activated receptor
alpha
59. Peroxisome proliferator activated receptor
delta
60. Peroxisome proliferator activated receptor
gamma
61. Estrogen related receptor, alpha
62. Estrogen-related receptor gamma
63. CCAAT/enhancer binding protein (C/EBP),
alpha
64. CCAAT/enhancer binding protein (C/EBP),
beta
65. CCAAT/enhancer binding protein (C/EBP),
beta
66. Sirtuin 1 ((silent mating type information
regulation 2, homolog) 1
67. Peroxisome proliferative activated receptor,
gamma, coactivator 1 alpha
68. Peroxisome proliferative activated receptor,
gamma, coactivator 1 beta
69. Forkhead box O1A
70. Forkhead box O3a (predicted)
71. Forkhead box A2
72. Lipin 1
73. Lipin 2 (predicted)
74. Sterol regulatory element binding factor 1
75. Nuclear respiratory factor 1 (predicted)
76. GA repeat binding protein, beta 1
77. Similar to myocyte enhancer factor 2C
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Ref seq

Gene symbol

NM_019372

Ppm2c

NM_145091

Pdp2

NM_012556
NM_024162
XM_573948
NM_001017960
NM_012672

Fabp1
Fabp3/SHP
Irs2
Thra
Thrb

NM_013196

Ppara

NM_013141

Ppard

NM_013124

Pparg

NM_001008511
NM_203336

Esrra
Esrrg

NM_012524

Cebpa

NM_024125

Cebpb

NM_024125

Cebpd

XM_228146

Sirt1

NM_031347

Ppargc1a

NM_176075

Ppargc1b

XM_342244
XM_215421
NM_012743
NM_001012111
XM_237521
XM_213329
XM_231566
XM_344606
NM_001014035

Foxo1a
Foxo3a
HNF3b/FoxA2
Lpin1
Lpin2
Srebf1
Nrf1
Gabpb1
LOC309957

Table 3.3: (continued).
Gene name
78. Nuclear receptor subfamily 2, group F,
member 2
79. Uncoupling protein 2 (mitochondrial, proton
carrier)
80. Uncoupling protein 3 (mitochondrial, proton
carrier)
81. Diacylglycerol O-acyltransferase 1
82. Diacylglycerol O-acyltransferase homolog 2
(mouse)
83. Superoxide dismutase 1
84. Superoxide dismutase 2, mitochondrial
85. Cytochrome c oxidase subunit IV
isoform 1
86. Citrate synthase
87. Deiodinase, iodothyronine, type II
88. NK2 transcription factor related, locus 5
(Drosophila)
89. Actin, beta
90. Ribosomal protein L13A
91. Glyceraldehyde-3-phosphate dehydrogenase
92. Genomic DNA Contamination control
93. Reverse Transcriptase control
94. Positive PCR control
95. Positive PCR control
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Ref seq

Gene symbol

NM_080778

Nr2f2

NM_019354

Ucp2

NM_013167

Ucp3

NM_053437

Dgat1

NM_001012345

Dgat2

NM_017050
NM_017051

Sod1
Sod2

NM_017202

Cox4i1

NM_130755
NM_031720

Cs
Dio2

NM_053651

Nkx2-5

NM_031144
NM_173340
NM_017008

ActB
RPL13A
GAPDH

CHAPTER 4: DISCUSSION
Both thyroid hormone (T3) and the transcriptional coregulators (transcriptional
factors & coactivators) play an important role in regulating the transcription of genes
involved in the glucose and fatty acid metabolism. In this study, I focused on the role of
the thyroid hormone receptor beta (TRβ), proliferator-activated receptor gamma
coactivator-1 alpha (PGC-1α) and the CCAAT/enhancer binding protein beta (C/EBPβ)
in the regulation of pyruvate dehydrogenase kinase 4 (PDK4) by thyroid hormone.
Pyruvate dehydrogenase kinases decrease the pyruvate dehydrogenase complex
(PDC) activity by phosphorylation, thereby inhibiting the conversion of pyruvate to
acetyl-CoA. Changes in PDC activity link glucose metabolism to fatty acid metabolism.
PDKs facilitate gluconeogenesis by inhibiting PDC and preserving the three carbon
compounds (pyruvate, lactate and alanine) as substrates for gluconeogenesis. At the same
time, PDC inhibition (via PDKs) allows the oxidation of fatty acids to be the primary
source of energy. Elevated gluconeogenesis and disturbance in fatty acid metabolism are
observed in metabolic diseases as diabetes, obesity and hyperthyroidism (Basu et al.,
2005; Baxter et al., 2004; Chevalier et al., 2006; Crunkhorn & Patti, 2008; Kabir et al.,
2005; Wensaas et al., 2009). My studies that focused on the mechanism by which thyroid
hormone regulates the transcription of the PDK4 gene and the role of the transcriptional
coregulators in this regulation, have shed light on the role of thyroid hormone in both the
glucose and fatty acid metabolism. In addition, I have provided a broad picture of the
network of transcription factors and coactivators involved in the hepatic regulation of T3
responsive metabolic genes.
4.1 Regulation of the PDK4 gene expression
4.1.1 The role of the thyroid hormone in the PDK4 gene expression
T3 is a prominent regulator of the PDK4 gene expression and activity in heart,
liver and skeletal muscles (Holness et al., 2003; Sugden et al., 2000a; Sugden et al.,
2000b). The transient transfection experiments done in this study showed that indeed T3
can induce PDK4 gene expression in vitro in hepatoma HepG2 cells and in vivo in
hyperthyroid rats. This stimulation was mediated through a TRE site found in the PDK4
gene promoter designated as (agggcaccttgggtaa) which resembles the direct repeat
separated by 4 nucleotides (DR4) type of TRE (Williams & Brent, 1995). We were the
first to identify a TRE site within the rPDK4 promoter indicating that T3 can activate the
PDK4 gene expression directly and not through an intermediate factor. However, the
identification of a TRE does not rule out a role of intermediate factors in the activation of
the T3 induction. Therefore, I studied the role PGC-1α and C/EBPβ as two potential
intermediate factors in this induction.
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4.1.2 The role of the PGC-1α in the induction of the PDK4 by thyroid hormone
Previous studies showed that there are links between the T3 metabolic actions and
PGC-1α. First, PGC-1α coactivated the thyroid receptors (Puigserver et al., 1998; Wu et
al., 2002). PGC-1α can also influence thyroid hormone action by altering RNA
processing of TRα transcripts, thus modulating the ratio of TRα1 and TRα2 isoforms
which is accompanied by a decrease in 5'-deiodinase expression (Thijssen-Timmer et al.,
2006). Second, Weitzel et al reported that the hepatic PGC-1α mRNA expression is
induced by T3 treatment (Weitzel et al., 2001). Third, the enhancement of the induction
of carnitine palmitoyltransferase 1a (CPT-1a) by thyroid hormone in the presence of
PGC-1α was reported in previous studies (Zhang et al., 2004b). Finally, a recent review
by Crunkhorn et al emphasized the potential linkage between PGC-1 coactivators and
thyroid hormone action on the mitochondrial oxidation pathway (Crunkhorn & Patti,
2008).
In agreement with the proposed role of the PGC-1α in the T3 action, my
experiments showed an association between the PGC-1α and both the proximal and the
TRE site in the PDK4 promoter in vivo indicated by ChIP technique. Previous studies had
reported that PGC-1α stimulated PDK4 (Wende et al., 2005). This association was
increased significantly by thyroid hormone. Moreover, T3 treatment induced the mRNA
and the protein level of both PDK4 and PGC-1α. In addition, overexpression of PGC-1α
showed significant synergistic effect on the T3 induction of PDK4 gene expression.
However, this synergistic effect was not abolished by mutating either the ERRα or the
FOXO1 binding sites, indicating that PGC-1α is involved in the PDK4 regulation not
only via the ERRα action but it can also exert its action through interacting with the TRs
(Puigserver et al., 1998; Wu et al., 2002).
Adenoviral-mediated silencing of the PGC-1α was utilized to investigate the role
of the PGC-1α in the induction of PDK4 and other metabolic genes by T3. This
experiment showed that silencing PGC-1α abolished the ability of T3 to induce PDK4,
CPT-1a, PEPCK and C/EBPβ gene expression indicating that PGC-1α is an important
coactivator for the T3 induction of these genes in primary hepatocytes. This experiment
contrasts with a recent study conducted by Wetizel’s group, as they reported that
silencing PGC-1α had no effect on the induction of gene expression by T3 in rat pituitary
(GC) cells (Wulf et al., 2007). In contrast with our studies, they measured the T3 effect
on two other genes, glycerol-3-phosphate dehydrogenase (GPDH) and adenine nucleotide
translocater 2 (ANT2). More importantly, they used GC pituitary cells, which are
subclone of the rat GH3 pituitary tumor cell line and posses a different gene expression
pattern than that of primary hepatocytes. The proliferation of GC cells are highly induced
by T3 treatment (Barrera-Hernandez et al., 1999; Kitagawa et al., 1987; Laverriere et al.,
1986; Miller et al., 2001; Nass et al., 2000). On the other hand, T3 has no effect on the
proliferation of hepatocytes in vitro (Kariv et al., 2003). All these data suggest that the T3
regulation in pituitary GC cells is likely different than that for primary hepatocytes. It is
also noteworthy that PGC-1α is underexpressed in immortalized tumor cell lines as it was
reported in human hepatoma cells (Martinez-Jimenez et al., 2006). In addition, The role
of PGC-1α in the T3 mediated gene expression in heart is still controversial. Two studies
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had indicated that PGC-1 is potentially involved in mediating myocardial-specific
remodeling of mitochondria in response to thyroid hormone treatment (Goldenthal et al.,
2004; McClure et al., 2005). However, two other studies had ruled out a role for the
PGC-1α in the cardiac mitochondrial adaptations by T3 (Athea et al., 2007; Irrcher et al.,
2003), although, Irrcher et al stated that PGC-1α is still involved in the mitochondrial
adaptation by T3 treatment in liver and skeletal muscles indicating that PGC-1α
involvement in the T3 mediated gene expression is potentially tissue specific (Irrcher et
al., 2003).
On the other hand, number of previous studies support the results from the
adenoviral-mediated silencing of PGC-1α experiment. One of these studies was
conducted by the Spiegelman’s group as they reported that C/EBPβ was abnormally
activated in the fed state in the PGC-1α null mice (Lin et al., 2004). Normally, fasting not
feeding induced C/EBPβ in wild type mice (Lin et al., 2004). C/EBPδ was also induced
in the fed liver lacking PGC-1α, while C/EBPα is expressed normally with respect to
PGC-1α genotypes indicating that silencing PGC-1α alters expression of specific C/EBP
isoforms. The aberrant induction of C/EBPβ and C/EBPδ, however, is absent when PGC1α-deficient hepatocytes are grown in cell culture, suggesting that systemic signals are
likely responsible for their increased expression (Lin et al., 2004). Although, this study
had linked the PGC-1α to the C/EBPβ gene induction by another physiological process
which is feeding or fasting status and not T3 action, however, it supports our results that
PGC-1α is an important regulator of C/EBPβ gene expression. Also, as supportive
evidence Crunkhorn and Patti had stated in their review, that their unpublished data
indicate that siRNA targeting PGC-1α or PGC-1β decreased the mRNA of TRα1 and
mitochondrial genes in skeletal muscle (Crunkhorn & Patti, 2008).
Based on the transient transfection, ChIP, and adenovirus mediating knockdown
experiments done in this dissertation, we can model the mechanism by which PGC-1α
coactivate the induction of PDK4 gene expression by T3 (Figure 4.1). In this model, T3
increases the abundance of the PGC-1α so that more PGC-1α will be available to
stimulate the PDK4 gene. PGC-1α can induce the PDK4 gene expression through the
interaction with the ERRα at the proximal part of the PDK4 promoter (Wende et al.,
2005; Zhang et al., 2006). Also, PGC-1α can synergistically coactivate the T3 induction
of the PDK4 gene by interacting with the TR and RXR at the TRE site of the PDK4
promoter, even after disrupting the ERRα binding sites.
4.1.3 The role of the C/EBPβ in the induction of the PDK4 by thyroid hormone
Although, our lab and others had reported that C/EBPα is involved in the T3
induction of number of genes (Jackson-Hayes et al., 2003; Jurado et al., 2002; Park et al.,
1997; Yin et al., 2005), to our knowledge only two studies had linked the C/EBPβ to T3
action. The first study was done by Menendez-Hurtado, in which he reported that both
C/EBPα and C/EBPβ gene expression decreased in liver of congenital hypothyroid rats
during development (Menendez-Hurtado et al., 1997). Upon injection of those
hypothyroid animals with thyroid hormone, there was an increase of hepatic C/EBPα and
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Figure 4.1: PGC-1α is a coactivator in the T3 induction of the PDK4 gene
expression.
T3 activates the PDK4 gene expression directly through a TRE site and indirectly by
stimulating the expression of the PGC-1α gene expression. Also, T3 increases the
association between PGC-1α and the PDK4 promoter.
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C/EBPβ mRNA and protein levels (Menendez-Hurtado et al., 1997). The second study
was carried out by our lab, and we reported that C/EBPβ overexpression enhanced the T3
induction of PEPCK (Park et al., 1999).
In this study we are the first to report that overexpression of the C/EBPβ in
transient transfections induced the PDK4 promoter. In addition, C/EBPβ enhanced the T3
induction of PDK4 gene expression. Also, T3 treatment induced the C/EBPβ gene
expression in primary hepatocytes. Moreover, adenoviral-mediated silencing of C/EBPβ
experiments demonstrated that C/EBPβ is required for full induction of PDK4 mRNA by
T3, as knocking down the C/EBPβ reduced the ability of T3 to induce PDK4 gene
expression. The Ad-siC/EBPβ did not reduce significantly the basal levels of PDK4
mRNA levels. These results are similar to studies done by the Friedman’s group, where
they reported that C/EBPβ is not essential for maintenance of the basal PEPCK mRNA
levels in C/EBPβ knockout mice (Arizmendi et al., 1999). However, C/EBPβ deletion
limited the full induction of PEPCK and glucose 6-phosphatase genes in streptozotocin
induced diabetic mice (Arizmendi et al., 1999). Although this study had linked C/EBPβ
as essential factor for metabolic and gene regulatory responses to diabetes, it did not
connect C/EBPβ to T3 action. However, C/EBPβ does modulate gluconeogenesis, a
process regulated by both PDK4 gene and T3 (Fowden et al., 2001; Park et al., 1997;
Sparks et al., 2006; Sugden & Holness, 2002). It is also noteworthy that C/EBPβ
participates in the regulation of the PEPCK gene in response to different stimulus like
cAMP, glucocorticoids and insulin (Croniger et al., 2001; Duong et al., 2002; Yamada et
al., 1999).
4.2 Transcription factors and metabolic genes involved in the thyroid hormone
network in primary hepatocytes
Previous studies had showed that T3 regulates different aspects of both glucose
and fatty acid metabolism. T3 simulates gluconeogenesis, cellular glucose uptake and
glycogenolysis (Crunkhorn & Patti, 2008; Fowden et al., 2001; Johnson, 2006; Park et
al., 1997). In addition, T3 stimulates triglyceride production, lipogenesis, lipolysis and
fatty acid oxidation (Feng et al., 2000; Moreno et al., 2008; Ness & Zhao, 1994; Pykalisto
et al., 1976; Ribeiro, 2008; Wahrenberg et al., 1994; Zhang et al., 2004b).
T3 exerts all these metabolic effects through inducing a network of transcription
coregulators and metabolic genes (Weitzel et al., 2003a; Weitzel et al., 2003b; Weitzel et
al., 2001). In this dissertation I used superarray® real time PCR arrays to identify
selected metabolic genes and transcription coregulators that are regulated by 24 hours of
T3 treatment in primary hepatocytes. Although, a similar experiment had been performed
by the Weitzel’s group, this experiment was done using a broad microarray technique
unlike my experimental approach which focused on transcription coregulators and
metabolic genes involved in glucose and fatty acid metabolism (Weitzel et al., 2003a).
Also, microarray sensitivity is different than real-time PCR sensitivity (Kubista et al.,
2006). Finally Wetizel’s experiment was done using RNA extracted from T3-treated
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hypothyroid rats and outcomes from these rats can be different than that done using RNA
extracted from cultured T3-treated primary hepatocytes from normal rats.
Indeed out of the 27 genes upregulated by T3 after 24 hours of treatment that I
have reported in this study, only 4 genes, the two transcription coactivators PGC-1α and
PGC-1β, Cytochrome P450 which is involved in both fatty acid oxidation and
gluconeogenesis (Lieber, 1999), and fatty acid binding protein 1(Fabp1) involved in fatty
acid metabolism (Kabir et al., 2005), are in common with that reported by Weitzel
(Weitzel et al., 2003a). However, many of the genes detected in my study had been
reported by previous studies to be stimulated by T3. In this study we reported the
upregulation of some transcription factors like sterol regulatory element binding
transcription factor (Srebf1), C/EBPβ, peroxisomal proliferator activated receptor delta
(PPARδ). These factors had been reported to be induced by T3 treatment by other studies
(de Lange et al., 2007; Menendez-Hurtado et al., 1997; Zhang et al., 2003). On the other
hand, to our knowledge we are the first to report the T3 induction of transcription factors
lipin gene isoforms 1 and 2, ERRγ, GA binding protein transcription factor, beta subunit
1 (Gabpb1), Sirtuin 1 (Sirt-1) and transcription coactivator homeobox protein NK-2
(NKx2.5). It is important to mention in this aspect that lipin 1 was reported to be an
amplifier of the PGC-1α /PPARα -mediated control of hepatic lipid metabolism and it
exerts its action by direct interacting with both PGC-1α and PPARα (Finck et al., 2006).
Also, Sirt-1 had been involved in the activation of PGC-1α by deacetylation (GerhartHines et al., 2007; Markus & Morris, 2008). Thus, upregulation of lipin 1 and Sirt-1 by
T3 may be another way to regulate the activity of PGC-1α.
Also, in this study we reported the T3 induction of genes involved in
gluconeogenesis, PEPCK and G6pase and solute carrier family 2 (facilitated glucose
transporter), member 4 (Slc2a4). All of them had been previously reported to be T3
responsive genes (Fowden et al., 2001; Park et al., 1997; Torrance et al., 1997). For genes
involved in fatty acid oxidation and synthesis, we are the first to report the T3 induction
of 3-ketoacyl-Coenzyme A thiolase alpha subunit (Hadha), fatty acid binding protein
3/small heterodimer partner (Fabp3/SHP), solute carrier family 25 carnitine/acylcarnitine
translocase member 20 (Slc25a20), solute carrier family 27 fatty acid transporter member
5 (Slc27a5) and acetyl-Coenzyme A carboxylase beta (Acacb). In addition, we reported
the upregulation of carnitine palmitoyltransferase 1a (CPT-1a) and fatty acid synthase
(FAS) by T3 treatment, which had been previously documented (Xiong et al., 1998;
Zhang et al., 2004b).
Finally, using this superarray technique we reported the T3 induction of
miscellaneous genes. First, deiodinase type II (Dio2) which is responsible for generation
of T3 from T4 predominantly in brain, pituitary, and brown adipose tissue in mammals
(Yen, 2001) and we detected its hepatic upregulation in response to T3 treatment. It was
recently reported that Dio2 mRNA was detectable by real time PCR in livers of cows and
in the livers of liver X receptors null mice (Capuco et al., 2008; Kalaany et al., 2005).
Second, we confirmed PDK4 (gene of interest of this dissertation) upregulation by T3
treatment. At last, uncoupling proteins 2 and 3 (UCP2 and UCP3) was also found to be
T3 responsive genes. UCP3 was previously reported to be induced by T3 treatment (de
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Lange et al., 2007), however to our knowledge we are the first to report upregulationn of
UCP2 by T3 treatment.
Thus, this part of the dissertation has pinpointed the network of transcription
coregulators and metabolic genes involved in T3 hepatic action. Further studies using
knockout mice or mice injected using virus mediating silencing of these genes can
indicate its importance in the T3 mediated hepatic gene expression.
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APPENDIX: SUPPLEMENTAL DATA FOR CHAPTER 4
PGC-1α is involved in the activation of different metabolic genes by thyroid
hormone. To further investigate the role of the PGC-1α in the T3 activation of other
metabolic genes, we examined whether we could observe increased association of PGC1α to PDK4, CPT-1a and PEPCK in hypothyroid and hyperthyroid rats. Rats were made
hypothyroid by the administration of propylthiouracil (PTU) and then they were treated
with 100nM of T3 for 24 hours. Pieces of the liver were minced in 1% formaldehyde and
then used in ChIP assays. Again we detected PGC-1α in the proximal region of the PDK4
gene promoter, and this association was increased by 5.9 ± 0.5 fold after T3 treatment.
However, we did not observe any association of PGC-1α with the TRE region of the
PDK4 gene promoter. In addition, we observed increased association of the PGC-1α both
the first intron and the TRE region of the CPT-1a gene promoter after T3 treatment by
6.4 ± 0.8 fold and 2.2 ± 0.5 fold, respectively. Also, increased association of the PGC-1α
with proximal region of the PEPCK gene promoter by 3.6 ± 0.8 fold was detected after
T3 treatment (Figure A.1A and A.1B).
T3 not only increased the association of the PGC-1α with the above genes
promoters, but it also increased the abundance of the PGC-1α protein itself in these
hyperthyroid rats by 2.8 ± 0.3 fold (Figure A.1C). The increased abundance and
association of the PGC-1α with different metabolic genes after T3 treatment suggests that
T3 activation can work through the PGC-1α in the activation PDK4 and other metabolic
genes.
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Figure A.1: PGC-1α association with T3 responsive genes is elevated in
hyperthyroid rats.
A. ChIP assays were conducted in liver samples from hypothyroid rats that were
untreated or exposed to T3 for 24 hours. The ChIP assays were conducted as outlined in
the materials and methods. Various portions of the PDK4, CPT-1a and PEPCK genes
were analyzed for the binding of PGC-1α. Representative PCR reactions are shown. B.
The binding of PGC-1α to the various genes was quantified using quantity one software.
The results are the summary of four independent hypothyroid and T3 rats. C. The
abundance of PGC-1α was quantified using western blot analysis. The PGC-1α
abundance was assessed using protein extracts from the same rats that were used for the
ChIP assays.
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Figure A.1: (continued).
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